WO2021063968A1 - Procédé et composition pour diagnostiquer une maladie pulmonaire chronique obstructive - Google Patents

Procédé et composition pour diagnostiquer une maladie pulmonaire chronique obstructive Download PDF

Info

Publication number
WO2021063968A1
WO2021063968A1 PCT/EP2020/077267 EP2020077267W WO2021063968A1 WO 2021063968 A1 WO2021063968 A1 WO 2021063968A1 EP 2020077267 W EP2020077267 W EP 2020077267W WO 2021063968 A1 WO2021063968 A1 WO 2021063968A1
Authority
WO
WIPO (PCT)
Prior art keywords
copd
spla2
inhibitor
xiia
subject
Prior art date
Application number
PCT/EP2020/077267
Other languages
English (en)
Inventor
Maylis DAGOUASSAT
Jorge Boczkowski
Danushki HERATH
Benjamin EVEN
Original Assignee
INSERM (Institut National de la Santé et de la Recherche Médicale)
Université Paris-Est Créteil Val De Marne
Assistance Publique-Hôpitaux De Paris (Aphp)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by INSERM (Institut National de la Santé et de la Recherche Médicale), Université Paris-Est Créteil Val De Marne, Assistance Publique-Hôpitaux De Paris (Aphp) filed Critical INSERM (Institut National de la Santé et de la Recherche Médicale)
Publication of WO2021063968A1 publication Critical patent/WO2021063968A1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/136Screening for pharmacological compounds
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Definitions

  • the invention relates to the field of medicine, and more particularly to the detection and treatment of chronic obstructive pulmonary disease.
  • COPD chronic obstructive pulmonary disease
  • telomeres are a state of irreversible growth arrest which can stem from shortening of telomeres during continuous cell replication (replicative senescence) or be triggered by other stressors, such as oxidative stress inducers (hydrogen peroxide, cigarette smoke, excessive ROS produced by a mitochondrial dysfunction) or inflammatory mediators (premature senescence) (7).
  • oxidative stress inducers hydroogen peroxide, cigarette smoke, excessive ROS produced by a mitochondrial dysfunction
  • inflammatory mediators premature senescence
  • senescent cells release several inflammatory mediators such as cytokines, chemokines, growth factors and MMPs referred as senescence-associated secretome or SASP (9).
  • SASP vascular endothelial growth factor
  • MCP-1 monocyte chemoattractant protein 1
  • CCL20 can induce senescence in heathy cells (Acosta et ah, 2013).
  • the SASP can reinforce both stress-induced, replicative and oncogene- induced senescence (OIS) growth arrest via IL-6 and IL-8 signaling, in a self-amplifying secretory network (10,11).
  • OIS oncogene- induced senescence
  • the clearance of senescent cells after a treatment with senolytics leads to an improvement of age-related diseases, suggesting that SASP suppression could explain the beneficial effects of senolysis.
  • cell senescence leads to a decreased regenerative capacity and an increased SASP by structural cells (epithelium, fibroblasts) (3,5,6).
  • the SASP secreted by these cells could play a major role in lung inflammation and remodeling in COPD.
  • the molecular mechanisms of senescence in COPD and specifically how senescence is maintained and propagated from cell to cell, and how this propagation is related to inflammation remain unknown.
  • PGE2 a lipid mediator derived from the metabolism of phospholipids by phospholipase A2 (PLA2) and cyclooxygenase (COX), participate to the propagation of the senescence in COPD lung fibroblasts (6). They went further in the investigation of this signaling pathway by focusing on secreted PLA2 (sPLA2).
  • This family contains 10 catalytically active isoforms (IB, IIA, IIC, IID, HE, IIF, III, V, X, and XIIA) and one inactive isoform (XIIB) in mammals (12).
  • sPLA2s are Ca2+ -dependent low - molecular weight (14 - 18 kDa) enzymes that are released in plasma and biological fluids of patients with various inflammatory diseases. Their biological effects depends on the binding of sPLA2s to two different receptors: soluble and membrane-bound M-type sPLA2 receptor (PLA2R1) which drives or counter regulates the biological effects induced by sPLA2 and heparan sulfate proteoglycans such as syndecans and glypicans (13,14). Only two studies have showed a link between sPLA2 and senescence.
  • the sPLA2 (IB and IIA) and the over expression of PLA2R1 have induced senescence in dermal fibroblasts and in cancer cells respectively, suggesting that such an effect could be observed in COPD fibroblasts (15,16).
  • the aim of the study was to investigate for the first time the potential role of sPLA2 XIIA in the senescence of lung COPD fibroblasts.
  • the invention relates to an in vitro method for diagnosing chronic obstructive pulmonary disease (COPD) in a subject, comprising the steps of (i) determining the expression level of the secreted PLA2XIIA in a sample obtained from said patient, and (ii) comparing the expression level determined at step i) with its predetermined reference value, and iii) concluding that the subject suffers from COPD when the expression level of the secreted sPLA2XIIA is higher than its predetermined reference value.
  • COPD chronic obstructive pulmonary disease
  • the invention in a second aspect, relates to an in vitro method for diagnosing chronic obstructive pulmonary disease (COPD) in a subject, comprising the steps of (i) determining the expression level of the receptors of sPLA2XIIA in a sample obtained from said patient, and (ii) comparing the expression level determined at step i) with its predetermined reference value, and iii) concluding that the subject suffers from COPD when the expression level of the receptors of sPLA2XIIA is higher than its predetermined reference value.
  • COPD chronic obstructive pulmonary disease
  • the invention in a third aspect, relates to a method for preventing or treating COPD, comprising the steps of: (i) performing the method for diagnosing COPD of the invention, and (ii) administering to said patient a therapeutically effective amount of a sPLA2XIIA inhibitors.
  • PGE2 a lipid mediator derived from the metabolism of phospholipase A2 (PLA2) and cyclooxygenase (COX)
  • PLA2 phospholipase A2
  • COX cyclooxygenase
  • sPLA2XIIA as a circulating biomarker of COPD and establish a requirement for sPLA2 XIIA inhibition for the treatment or prevention of COPD.
  • invention relates to an in vitro method for diagnosing chronic obstructive pulmonary disease (COPD) in a subject, comprising the steps of (i) determining the expression level of the secreted PLA2 XIIA (sPLA2 XIIA) in a biological sample obtained from said patient, and (ii) comparing the expression level determined at step i) with its predetermined reference value, and iii) concluding that the subject suffers from COPD when the expression level of the secreted sPLA2 XIIA is higher than its predetermined reference value.
  • COPD chronic obstructive pulmonary disease
  • the invention in another aspect, relates to an in vitro method for diagnosing chronic obstructive pulmonary disease (COPD) in a subject, comprising the steps of (i) determining the expression level of at least one sPLA2 XIIA receptor selected among PLA2R1, syndecan and glypican in a biological sample obtained from said subject, (ii) comparing the expression level determined at step i) with its predetermined reference value, and iii) concluding that the subject suffers from COPD when the expression level of the sPLA2 XIIA receptors is higher than its predetermined reference value.
  • COPD chronic obstructive pulmonary disease
  • the sPLA2 XIIA receptor whose expression level is determined in step i) is PLA2R1. In one embodiment, the sPLA2 XIIA receptor whose expression level is determined in step i) is syndecan.
  • the sPLA2 XIIA receptor whose expression level is determined in step i) is glypican.
  • the sPLA2 XIIA receptors whose expression level are determined in step i) are PLA2R1 and syndecan.
  • the sPLA2 XIIA receptors whose expression level are determined in step i) are PLA2R1 and glypican.
  • the sPLA2 XIIA receptors whose expression level are determined in step i) are PLA2R1, glypican and syndecan.
  • the sPLA2 XIIA receptors expression can be determined with sPLA2 XIIA expression to diagnose COPD.
  • the invention relates to an in vitro method for diagnosing chronic obstructive pulmonary disease (COPD) in a subject, comprising the steps of: (i) determining the expression level of sPLA2 XIIA and/or at least one sPLA2 XIIA receptors selected among PLA2R1, syndecan and glypican in a biological sample obtained from said subject, (ii) comparing the expression level determined at step i) with its predetermined reference value, and iii) concluding that the subject is at risk of having COPD when the expression level of the sPLA2 XIIA receptors is higher than its predetermined reference value.
  • COPD chronic obstructive pulmonary disease
  • the glypican whose expression level are determined according to the invention are glypican- 1, glypican-4 and/or glypican-6.
  • the syndecan whose expression level are determined in step i) are syndecan- 1 and/or syndecan-4.
  • the syndecan whose expression level are determined in step i) is syndecan-4.
  • diagnosis refers to classifying a disease or a symptom, determining a severity of the disease, monitoring disease progression, forecasting an outcome of a disease and/or prospects of recovery.
  • COPD chronic obstructive pulmonary disease
  • GOLD Global Initiative for Chronic Obstructive Lung Disease
  • secreted phospholipase A2 group XIIA or “sPLA2 XII A” refers to one of catalytically active isoforms of secreted phospholipase A2 (sPLA2) which catalyzes the calcium-dependent hydrolysis of the 2-acyl groups in 3-sn phosphoglycerides.
  • the sequence of said protein can be found under the Uniprot accession number Q9BZM1.
  • sPLA2s are released in plasma and biological fluids of patients with various inflammatory diseases.
  • sPLA2 has been shown to promote inflammation in mammals by catalyzing the first step of the arachidonic acid pathway by breaking down phospholipids, resulting in the formation of fatty acids including arachidonic acid.
  • sPLA2s act through specific receptors: soluble and membrane-bound M-type sPLA2 receptor (PLA2R1) and heparan sulfate proteoglycans such as syndecans and glypicans.
  • PKA2R1 soluble and membrane-bound M-type sPLA2 receptor
  • PHA2R1 has its general meaning in the art and refers to the secretory phospholipase A2 receptor.
  • the sequence of said protein can be found under the Uniprot accession number QUO 18.
  • syndecan has its general meaning in the art and refers to a single transmembrane domain proteins acting as coreceptors for G protein-coupled receptors.
  • the syndecan protein family has four members: syndecan- 1, -2, -3 and -4 whose the amino acid length is 310, 201, 346 and 198 respectively.
  • the subclassification of the family depending on the existence of GAG binding sites either at both ends of the ectodomain (syndecan- 1 and -3) or at the distal part only (syndecan-2 and -4) and a relatively long Thr-Ser-Pro-rich area in the middle of syndecan- 3’s ectodomain.
  • the sequence of protein syndecan- 1, -2, -3, and -4 can be found under the Uniprot accession number P18827, P34741, 075056 and P31431, respectively.
  • glypican has its general meaning in the art and refers to heparan sulfate proteoglycans. Glypicans are critically involved in developmental morphogenesis, and have been implicated as regulators in several cell signaling pathways. These include the Wnt and Hedgehog signaling pathways, as well as signaling of fibroblast growth factors and bone morphogenic proteins. The regulating processes performed by glypicans can either stimulate or inhibit specific cellular processes.
  • the glypican protein family has six members: glypican- 1, -2, -3 -4, -5 and -6 whose the protein sequence can be found under the Uniprot accession number P35052, Q8N158, P51654, 075487, P78333 and Q9Y625 respectively.
  • the term “subject” refers to any mammals, such as a rodent, a feline, a canine, and a primate.
  • the subject is a human.
  • the subject is a human who is susceptible to have COPD.
  • biological sample in the context of the present invention is a biological sample isolated from a subject and can include, by way of example and not limitation, bodily fluids and/or tissue extracts such as homogenates or solubilized tissue obtained from a subject. Tissue extracts are obtained routinely from tissue biopsy and autopsy material. Bodily fluids useful in the present invention include blood, bone marrow aspirate, urine, saliva, broncho-alveolar lavage (LBA) or any other bodily secretion or derivative thereof. As used herein "blood” includes whole blood, plasma, serum, circulating cells, constituents, or any derivative of blood. In a particular embodiment, the biological sample is a serum sample or a lung tissue sample.
  • bodily fluids and/or tissue extracts such as homogenates or solubilized tissue obtained from a subject. Tissue extracts are obtained routinely from tissue biopsy and autopsy material.
  • Bodily fluids useful in the present invention include blood, bone marrow aspirate, urine, saliva, broncho-alveolar lavage
  • a “reference value” can be a “threshold value” or a “cut-off value”.
  • a “threshold value” or “cut-off value” can be determined experimentally, empirically, or theoretically.
  • a threshold value can also be arbitrarily selected based upon the existing experimental and/or clinical conditions, as would be recognized by a person of ordinary skilled in the art. The threshold value has to be determined in order to obtain the optimal sensitivity and specificity according to the function of the test and the benefit/risk balance (clinical consequences of false positive and false negative).
  • the optimal sensitivity and specificity (and so the threshold value) can be determined using a Receiver Operating Characteristic (ROC) curve based on experimental data.
  • ROC Receiver Operating Characteristic
  • the person skilled in the art may compare the sPLA2 XIIA, PLA2R1, syndecan or glypican expression level (obtained according to the method of the invention) with a defined threshold value.
  • the threshold value may also be derived from sPLA2 XIIA, PLA2R1, syndecan or glypican expression level (or ratio, or score) determined in a sample derived from one or more COPD patients. Furthermore, retrospective measurement of the sPLA2 XIIA, PLA2R1, syndecan or glypican level (or ratio, or scores) in properly banked historical patients samples may be used in establishing these threshold values. Reference values are easily determinable by the one skilled in the art, by using the same techniques as for determining the level of sSPLA2 XIIA, PLA2R1, syndecan or glypican expression level in samples previously collected from the patient under testing.
  • An additional object of the invention relates to an in vitro method for determining whether is at risk of having COPD in a subject, comprising the steps of (i) determining the expression level of sPLA2 XIIA and/or at least one sPLA2XIIA receptors selected among PLA2R1, syndecan and glypican in a biological sample obtained from said subject, (ii) comparing the expression levels determined at step (i) with their predetermined reference value, and iii) concluding that the subject is at risk of having COPD when the expression levels determined at step (i) is higher than their predetermined reference value.
  • risk relates to the probability that an event will occur over a specific time period, as in the conversion to COPD, and can mean a subject's "absolute” risk or “relative” risk.
  • Absolute risk can be measured with reference to either actual observation post measurement for the relevant time cohort, or with reference to index values developed from statistically valid historical cohorts that have been followed for the relevant time period.
  • Relative risk refers to the ratio of absolute risks of a subject compared either to the absolute risks of low risk cohorts or an average population risk, which can vary by how clinical risk factors are assessed.
  • Odds ratios the proportion of positive events to negative events for a given test result, are also commonly used (odds are according to the formula p/(l-p) where p is the probability of event and (1- p) is the probability of no event) to no conversion.
  • An another object of the invention relates to an in vitro method for predicting the survival time of a subject suffering from COPD comprising the steps of (i) determining the expression level of sPLA2 XIIA and/or at least one sPLA2XIIA receptors selected among PLA2R1, syndecan and glypican in a biological sample obtained from said subject, (ii) comparing the expression levels determined at step (i) with their predetermined reference value, and iii) providing a good prognosis when the expression level determined at step (i) is lower than their predetermined reference value, or providing a bad prognosis when the expression level determined at step (i) is higher.
  • methods according to the invention may be useful for predicting the overall survival (OS) of a patient suffering from COPD or for predicting the free survival (FS) of a patient suffering from COPD.
  • OS overall survival
  • FS free survival
  • the invention relates to an in vitro method for predicting the overall survival (OS) of a patient suffering from COPD comprising the steps of (i) determining the expression level of sPLA2 XIIA and/or at least one sPLA2XIIA receptors selected among PLA2R1, syndecan and glypican in a biological sample obtained from said subject, (ii) comparing the expression levels determined at step (i) with their predetermined reference value, and iii) providing a good prognosis when the expression level determined at step (i) is lower than their predetermined reference value, or providing a bad prognosis when the expression level determined at step (i) is higher than their predetermined reference value.
  • the invention relates to an in vitro method for predicting the free survival (FS) of a patient suffering from COPD comprising the steps of (i) determining the expression level of sPLA2 XIIA and/or at least one sPLA2XIIA receptors selected among PLA2R1, syndecan and glypican in a biological sample obtained from said subject, (ii) comparing the expression levels determined at step (i) with their predetermined reference value, and iii) providing a good prognosis when the expression level determined at step (i) is lower than their predetermined reference value, or providing a bad prognosis when the expression level determined at step (i) is higher than their predetermined reference value.
  • OS Overall survival
  • AML AML
  • the overall survival rate is often stated as a five-year survival rate, which is the percentage of people in a study or treatment group who are alive five years after their diagnosis or the start of treatment.
  • FS Free Survival
  • Event-Free- Survival denotes the length of time after primary treatment for a cancer ends that the patient remains free of certain complications or events that the treatment was intended to prevent or delay. These events may include the return of the cancer or the onset of certain symptoms, such as bone pain from cancer that has spread to the bone.
  • the expression level of the markers may also be measured by measuring the protein or mRNA expression level can be performed by a variety of techniques well known in the art.
  • protein expression level may be measured for example by capillary electrophoresis-mass spectroscopy technique (CE-MS), flow cytometry, mass cytometry or ELISA performed on the sample.
  • CE-MS capillary electrophoresis-mass spectroscopy technique
  • the “level of protein” or the “protein level expression” means the quantity or concentration of said protein.
  • the protein is expressed at the cell surface for markers whose function is linked to their correct plasma membrane expression or total expression for markers whose function is not limited to membrane expression.
  • the “level of protein” means the quantitative measurement of the proteins expression relative to a negative control.
  • Such methods comprise contacting a sample with a binding partner capable of selectively interacting with proteins present in the sample.
  • the binding partner is generally an antibody that may be polyclonal or monoclonal, preferably monoclonal.
  • the presence of the protein can be detected using standard electrophoretic and immunodiagnostic techniques, including immunoassays such as competition, direct reaction, or sandwich type assays.
  • immunoassays such as competition, direct reaction, or sandwich type assays.
  • assays include, but are not limited to, Western blots; agglutination tests; enzyme-labeled and mediated immunoassays, such as ELISAs; biotin/avidin type assays; radioimmunoassays; immunoelectrophoresis; immunoprecipitation, capillary electrophoresis- mass spectroscopy technique (CE-MS).DOT BLOT etc.
  • the reactions generally include revealing labels such as fluorescent, chemioluminescent, radioactive, enzymatic labels or dye molecules, or other methods for detecting the formation of a complex between the antigen and the antibody or antibodies reacted therewith.
  • the aforementioned assays generally involve separation of unbound protein in a liquid phase from a solid phase support to which antigen-antibody complexes are bound.
  • Solid supports which can be used in the practice of the invention include substrates such as nitrocellulose (e. g., in membrane or microtiter well form); polyvinylchloride (e. g., sheets or microtiter wells); polystyrene latex (e.g., beads or microtiter plates); polyvinylidine fluoride; diazotized paper; nylon membranes; activated beads, magnetically responsive beads, and the like.
  • an ELISA method can be used, wherein the wells of a microtiter plate are coated with a set of antibodies against the proteins to be tested.
  • a sample containing or suspected of containing the marker protein sPLA2 XIIA, PLA2R1, syndecan or glypican
  • the plate(s) can be washed to remove unbound moieties and a detectably labeled secondary binding molecule is added.
  • the secondary binding molecule is allowed to react with any captured sample marker protein, the plate is washed and the presence of the secondary binding molecule is detected using methods well known in the art.
  • Mass spectrometry-based quantification methods may be used. Mass spectrometry-based quantification methods may be performed using either labelled or unlabelled approaches [DeSouza and Siu, 2012] Mass spectrometry-based quantification methods may be performed using chemical labeling, metabolic labeling or proteolytic labeling. Mass spectrometry-based quantification methods may be performed using mass spectrometry label free quantification, a quantification based on extracted ion chromatogram (EIC) and then profile alignment to determine differential level of polypeptides.
  • EIC extracted ion chromatogram
  • a mass spectrometry-based quantification method particularly useful can be the use of targeted mass spectrometry methods as selected reaction monitoring (SRM), multiple reaction monitoring (MRM), parallel reaction monitoring (PRM), data independent acquisition (DIA) and sequential window acquisition of all theoretical mass spectra (SWATH) [Moving target Zeliadt N 2014 The Computer;Liebler Zimmerman Biochemistry 2013 targeted quantitation pf proteins by mass spectrometry; Gallien Domon 2015 Detection and quantification of proteins in clinical samples using high resolution mass spectrometry. Methods v81 pl5-23; Sajic, Liu, Aebersold, 2015 Using data-independent, high-resolution mass spectrometry in protein biomarker research: perspectives and clinical applications. Proteomics Clin Appl v9 p 307-21]
  • the mass spectrometry-based quantification method can be the mass cytometry also known as cytometry by time of flight (CYTOF) (Bandura DR, Analytical chemistry, 2009).
  • CYTOF cytometry by time of flight
  • the mass spectrometry-based quantification is used to do peptide and/or protein profiling can be use with matrix-assisted laser desorption/ionisation time of flight (MALDI-TOF), surface-enhanced laser desorption/ionization time of flight (SELDI-TOF; CLINPROT) and MALDI Biotyper apparatus [Solassol, Jacot, Lhermitte, Boulle, Maudelonde, Mange 2006 Clinical proteomics and mass spectrometry profiling for cancer detection. Journal: Expert Review of Proteomics V3, 13, p311-320 ; FDA K130831]
  • MALDI-TOF matrix-assisted laser desorption/ionisation time of flight
  • SELDI-TOF surface-enhanced laser desorption/ionization time of flight
  • MALDI Biotyper apparatus Solassol, Jacot, Lhermitte, Boulle, Maudelonde, Mange 2006 Clinical proteomics and mass spectrometry profiling for cancer detection. Journal:
  • Methods of the invention may comprise a step consisting of comparing the proteins and fragments concentration in circulating cells with a control value.
  • concentration of protein refers to an amount or a concentration of a transcription product, for instance the proteins of the invention.
  • a level of a protein can be expressed as nanograms per microgram of tissue or nanograms per milliliter of a culture medium, for example.
  • relative units can be employed to describe a concentration.
  • concentration of proteins may refer to fragments of the proteins of the invention.
  • measuring the expression level of the mRNA selected from the group consisting of sPLA2 XIIA PLA2R1, syndecan and glypican in a sample obtained from the subject can be performed by a variety of techniques.
  • the nucleic acid contained in the samples is first extracted according to standard methods, for example using lytic enzymes or chemical solutions or extracted by nucleic-acid-binding resins following the manufacturer's instructions.
  • the expression level of one or more mRNA in the sample may be determined by any suitable method. Any reliable method for measuring the level or amount of mRNA in a sample may be used.
  • mRNA can be detected and quantified from a sample (including fractions thereof), such as samples of isolated RNA by various methods, including, for example, amplification-based methods (e.g., Polymerase Chain Reaction (PCR), Real-Time Polymerase Chain Reaction (RT-PCR), Quantitative Polymerase Chain Reaction (qPCR), rolling circle amplification, etc.), hybridization-based methods (e.g., hybridization arrays (e.g., microarrays), NanoString analysis, Northern Blot analysis, branched DNA (bDNA) signal amplification, in situ hybridization, etc.), and sequencing-based methods (e.g., next- generation sequencing methods, for example, using the Illumina or IonTorrent platforms).
  • Other exemplary techniques include ribonuclease protection assay (RPA) and mass spectroscopy.
  • amplification-based methods exist for detecting the expression level of mRNA nucleic acid sequences, including, but not limited to, PCR, RT-PCR, qPCR, and rolling circle amplification.
  • Other amplification-based techniques include, for example, ligase chain reaction (LCR), multiplex ligatable probe amplification, in vitro transcription (IVT), strand displacement amplification (SDA), transcription-mediated amplification (TMA), nucleic acid sequence based amplification (NASBA), RNA (Eberwine) amplification, and other methods that are known to persons skilled in the art.
  • LCR ligase chain reaction
  • IVTT in vitro transcription
  • SDA strand displacement amplification
  • TMA transcription-mediated amplification
  • NASBA nucleic acid sequence based amplification
  • RNA (Eberwine) amplification and other methods that are known to persons skilled in the art.
  • a typical PCR reaction includes multiple steps, or cycles, that selectively amplify target nucleic acid species: a denaturing step, in which a target nucleic acid is denatured; an annealing step, in which a set of PCR primers (i.e., forward and reverse primers) anneal to complementary DNA strands, and an elongation step, in which a thermostable DNA polymerase elongates the primers. By repeating these steps multiple times, a DNA fragment is amplified to produce an amplicon, corresponding to the target sequence.
  • Typical PCR reactions include 20 or more cycles of denaturation, annealing, and elongation.
  • a reverse transcription reaction (which produces a cDNA sequence having complementarity to a mRNA) may be performed prior to PCR amplification.
  • Reverse transcription reactions include the use of, e.g., a RNA-based DNA polymerase (reverse transcriptase) and a primer.
  • Kits for quantitative real time PCR of mRNA are known, and are commercially available. Examples of suitable kits include, but are not limited to, the High Capacity RNA-to-cDNATM kit (Applied Biosystems) and the iScriptTM Advanced cDNA synthesis kit (Bio-Rad).
  • the mRNA can be ligated to a single stranded oligonucleotide containing universal primer sequences, a polyadenylated sequence, or adaptor sequence prior to reverse transcriptase and amplified using a primer complementary to the universal primer sequence, poly(T) primer, or primer comprising a sequence that is complementary to the adaptor sequence.
  • custom qRT-PCR assays can be developed for determination of mRNA levels. Custom qRT-PCR assays to measure mRNAs in a sample can be developed using, for example, methods that involve an extended reverse transcription primer and locked nucleic acid modified PCR.
  • Custom mRNA assays can be tested by running the assay on a dilution series of chemically synthesized mRNA corresponding to the target sequence. This permits determination of the limit of detection and linear range of quantitation of each assay. Furthermore, when used as a standard curve, these data permit an estimate of the absolute abundance of mRNAs measured in the samples. Amplification curves may optionally be checked to verify that Ct values are assessed in the linear range of each amplification plot. Typically, the linear range spans several orders of magnitude. For each candidate mRNA assayed, a chemically synthesized version of the mRNA can be obtained and analyzed in a dilution series to determine the limit of sensitivity of the assay, and the linear range of quantitation.
  • Relative expression levels may be determined, for example, according to the 2(- DD C(T)) Method, as described by Livak et ah, Analysis of relative gene expression data using real-time quantitative PCR and the 2(-DD C(T)) Method. Methods (2001) Dec;25(4):402-8.
  • two or more mRNAs are amplified in a single reaction volume.
  • multiplex q-PCR such as qRT-PCR, enables simultaneous amplification and quantification of at least two mRNAs of interest in one reaction volume by using more than one pair of primers and/or more than one probe.
  • the primer pairs comprise at least one amplification primer that specifically binds each mRNA, and the probes are labeled such that they are distinguishable from one another, thus allowing simultaneous quantification of multiple mRNAs.
  • Rolling circle amplification is a DNA-polymerase driven reaction that can replicate circularized oligonucleotide probes with either linear or geometric kinetics under isothermal conditions (see, for example, Lizardi et al, Nat. Gen. (1998) 19(3):225-232; Gusev et al, Am. J. Pathol. (2001) 159(l):63-69; Nallur et al, Nucleic Acids Res. (2001) 29(23):E118).
  • a complex pattern of strand displacement results in the generation of over 109 copies of each DNA molecule in 90 minutes or less.
  • Tandemly linked copies of a closed circle DNA molecule may be formed by using a single primer.
  • the process can also be performed using a matrix- associated DNA.
  • the template used for rolling circle amplification may be reverse transcribed. This method can be used as a highly sensitive indicator of mRNA sequence and expression level at very low mRNA concentrations (see, for example, Cheng et al., Angew Chem. Int. Ed. Engl. (2009) 48(18):3268-72; Neubacher et al, Chembiochem. (2009) 10(8): 1289-91).
  • mRNA quantification may be performed by using stem-loop primers for reverse transcription (RT) followed by a real-time TaqMan® probe.
  • said method comprises a first step wherein the stem-loop primers are annealed to mRNA targets and extended in the presence of reverse transcriptase. Then mRNA-specific forward primer, TaqMan® probe, and reverse primer are used for PCR reactions. Quantitation of mRNAs is estimated based on measured CT values. Many mRNA quantification assays are commercially available from Qiagen (S. A. Courtaboeuf, France), Exiqon (Vedbaek, Denmark) or Applied Biosystems (Foster City, USA).
  • Nucleic acids exhibiting sequence complementarity or homology to the mRNAs of interest herein find utility as hybridization probes or amplification primers. It is understood that such nucleic acids need not be identical, but are typically at least about 80% identical to the homologous region of comparable size, more preferably 85% identical and even more preferably 90-95% identical. In certain embodiments, it will be advantageous to use nucleic acids in combination with appropriate means, such as a detectable label, for detecting hybridization. A wide variety of appropriate indicators are known in the art including, fluorescent, radioactive, enzymatic or other ligands (e. g. avidin/biotin). mRNA may be detected using hybridization-based methods, including but not limited to hybridization arrays (e.g., microarrays), NanoString analysis, Northern Blot analysis, branched DNA (bDNA) signal amplification, and in situ hybridization.
  • hybridization arrays e.g., microarrays
  • NanoString analysis e.g., Northern Blo
  • Microarrays can be used to measure the expression levels of large numbers of mRNAs simultaneously.
  • Microarrays can be fabricated using a variety of technologies, including printing with fine-pointed pins onto glass slides, photolithography using pre- made masks, photolithography using dynamic micromirror devices, inkjet printing, or electrochemistry on microelectrode arrays. Also useful are microfluidic TaqMan Low-Density Arrays, which are based on an array of micro fluidic qRT-PCR reactions, as well as related microfluidic qRT-PCR based methods.
  • Microarrays can be used for the expression profiling of mRNAs.
  • RNA can be extracted from the sample and, optionally, the mRNAs are size- selected from total RNA.
  • Oligonucleotide linkers can be attached to the 5' and 3' ends of the mRNAs and the resulting ligation products are used as templates for an RT-PCR reaction.
  • the sense strand PCR primer can have a fluorophore attached to its 5' end, thereby labeling the sense strand of the PCR product.
  • the PCR product is denatured and then hybridized to the microarray.
  • a PCR product referred to as the target nucleic acid that is complementary to the corresponding mRNA capture probe sequence on the array will hybridize, via base pairing, to the spot at which the capture probes are affixed.
  • the spot will then fluoresce when excited using a microarray laser scanner.
  • the fluorescence intensity of each spot is then evaluated in terms of the number of copies of a particular mRNA, using a number of positive and negative controls and array data normalization methods, which will result in assessment of the level of expression of a particular mRNA.
  • Total RNA containing the mRNA extracted from the sample can also be used directly without size-selection of the mRNAs.
  • the RNA can be 3' end labeled using T4 RNA ligase and a fluorophore-labeled short RNA linker.
  • Fluorophore-labeled mRNAs complementary to the corresponding mRNA capture probe sequences on the array hybridize, via base pairing, to the spot at which the capture probes are affixed.
  • the fluorescence intensity of each spot is then evaluated in terms of the number of copies of a particular mRNA, using a number of positive and negative controls and array data normalization methods, which will result in assessment of the level of expression of a particular mRNA.
  • Several types of microarrays can be employed including, but not limited to, spotted oligonucleotide microarrays, pre-fabricated oligonucleotide microarrays or spotted long oligonucleotide arrays.
  • the expression level is determined by DNA chip analysis.
  • DNA chip or nucleic acid microarray consists of different nucleic acid probes that are chemically attached to a substrate, which can be a microchip, a glass slide or a microsphere-sized bead.
  • a microchip may be constituted of polymers, plastics, resins, polysaccharides, silica or silica-based materials, carbon, metals, inorganic glasses, or nitrocellulose.
  • Probes comprise nucleic acids such as cDNAs or oligonucleotides that may be about 10 to about 60 base pairs.
  • a sample from a test subject optionally first subjected to a reverse transcription, is labelled and contacted with the microarray in hybridization conditions, leading to the formation of complexes between target nucleic acids that are complementary to probe sequences attached to the microarray surface.
  • the labelled hybridized complexes are then detected and can be quantified or semi-quantified. Labelling may be achieved by various methods, e.g. by using radioactive or fluorescent labelling.
  • Many variants of the microarray hybridization technology are available to the man skilled in the art (see e.g. the review by Hoheisel, Nature Reviews, Genetics, 2006, 7:200-210).
  • the nucleic acid probes include one or more labels, for example to permit detection of a target nucleic acid molecule using the disclosed probes.
  • a nucleic acid probe includes a label (e.g., a detectable label).
  • a “detectable label” is a molecule or material that can be used to produce a detectable signal that indicates the presence or concentration of the probe (particularly the bound or hybridized probe) in a sample.
  • a labeled nucleic acid molecule provides an indicator of the presence or concentration of a target nucleic acid sequence can be detected either directly or indirectly.
  • a label can be detected by any known or yet to be discovered mechanism including absorption, emission and/ or scattering of a photon (including radio frequency, microwave frequency, infrared frequency, visible frequency and ultra-violet frequency photons).
  • Detectable labels include colored, fluorescent, phosphorescent and luminescent molecules and materials, catalysts (such as enzymes) that convert one substance into another substance to provide a detectable difference (such as by converting a colorless substance into a colored substance or vice versa, or by producing a precipitate or increasing sample turbidity), haptens that can be detected by antibody binding interactions, and paramagnetic and magnetic molecules or materials.
  • detectable labels include fluorescent molecules (or fluorochromes).
  • fluorescent molecules or fluorochromes
  • Numerous fluorochromes are known to those of skill in the art, and can be selected, for example from Life Technologies (formerly Invitrogen), e.g., see, The Handbook- A Guide to Fluorescent Probes and Labeling Technologies).
  • fluorophores that can be attached (for example, chemically conjugated) to a nucleic acid molecule (such as a uniquely specific binding region) are provided in U.S. Pat. No.
  • Nazarenko et ah such as 4-acetamido-4'-isothiocyanatostilbene-2,2' disulfonic acid, acridine and derivatives such as acridine and acridine isothiocyanate, 5-(2'-aminoethyl) aminonaphthalene-1 -sulfonic acid (EDANS), 4-amino -N- [3 vinylsulfonyl)phenyl]naphthalimide-3,5 disulfonate (Lucifer Yellow VS), N-(4-anilino-l- naphthyl)maleimide, Brilliant Yellow, coumarin and derivatives such as coumarin, 7-amino-4- methylcoumarin (AMC, Coumarin 120), 7-amino-4-trifluoromethylcoumarin (Coumarin 151); cyanosine; 4',6-diarninidino-2-phenylindole (DAPI); 5
  • fluorophores include thiol-reactive europium chelates which emit at approximately 617 mn (Heyduk and Heyduk, Analyt. Biochem. 248:216-27, 1997; J. Biol. Chem. 274:3315-22, 1999), as well as GFP, LissamineTM, diethylaminocoumarin, fluorescein chlorotriazinyl, naphthofluorescein, 4,7-dichlororhodamine and xanthene (as described in U.S. Pat. No. 5,800,996 to Lee et al.) and derivatives thereof.
  • fluorophores known to those skilled in the art can also be used, for example those available from Life Technologies (Invitrogen; Molecular Probes (Eugene, Oreg.)) and including the ALEXA FLUOR® series of dyes (for example, as described in U.S. Pat. Nos. 5,696,157, 6, 130, 101 and 6,716,979), the BODIPY series of dyes (dipyrrometheneboron difluoride dyes, for example as described in U.S. Pat. Nos.
  • a fluorescent label can be a fluorescent nanoparticle, such as a semiconductor nanocrystal, e.g., a QUANTUM DOTTM (obtained, for example, from Life Technologies (QuantumDot Corp, Invitrogen Nanocrystal Technologies, Eugene, Oreg.); see also, U.S. Pat. Nos. 6,815,064; 6,682,596; and 6,649, 138).
  • Semiconductor nanocrystals are microscopic particles having size-dependent optical and/or electrical properties.
  • a secondary emission of energy occurs of a frequency that corresponds to the bandgap of the semiconductor material used in the semiconductor nanocrystal. This emission can he detected as colored light of a specific wavelength or fluorescence.
  • Semiconductor nanocrystals with different spectral characteristics are described in e.g., U.S. Pat. No. 6,602,671.
  • semiconductor nanocrystals can be produced that are identifiable based on their different spectral characteristics.
  • semiconductor nanocrystals can be produced that emit light of different colors based on their composition, size or size and composition.
  • quantum dots that emit light at different wavelengths based on size (565 nm, 655 nm, 705 nm, or 800 nm emission wavelengths), which are suitable as fluorescent labels in the probes disclosed herein are available from Life Technologies (Carlsbad, Calif.).
  • thermocyclers typically involve a format of glass capillaries, plastics tubes, 96-well plates or 384-well plates.
  • the thermocylcer also involves software analysis. mRNAs can also be detected without amplification using the nCounter Analysis System (NanoString Technologies, Seattle, WA).
  • This technology employs two nucleic acid-based probes that hybridize in solution (e.g., a reporter probe and a capture probe). After hybridization, excess probes are removed, and probe/target complexes are analyzed in accordance with the manufacturer's protocol.
  • nCounter RNA assay kits are available from NanoString Technologies, which are capable of distinguishing between highly similar mRNAs with great specificity.
  • RNA endonucleases RNases
  • MS/MS tandem MS
  • MALDI-MS Matrix-assisted laser desorption/ionization mass spectrometry
  • MALDI-MS has also been used as an analytical approach for obtaining information about post-transcriptionally modified nucleosides.
  • MALDI- based approaches can be differentiated from EST-based approaches by the separation step.
  • the mass spectrometer is used to separate the mRNA.
  • Additional methods for mRNA detection and measurement include, for example, strand invasion assay (Third Wave Technologies, Inc.), surface plasmon resonance (SPR), cDNA, MTDNA (metallic DNA; Advance Technologies, Saskatoon, SK), and single-molecule methods such as the one developed by US Genomics.
  • Multiple mRNAs can be detected in a microarray format using a novel approach that combines a surface enzyme reaction with nanoparticle-amplified SPR imaging (SPRI).
  • SPRI nanoparticle-amplified SPR imaging
  • the surface reaction of poly(A) polymerase creates poly(A) tails on miRNAs hybridized onto locked nucleic acid (LNA) microarrays. DNA-modified nanoparticles are then adsorbed onto the poly(A) tails and detected with SPRI.
  • mRNA profiling at attamole levels can be used for mRNA profiling at attamole levels.
  • mRNAs can also be detected using branched DNA (bDNA) signal amplification (see, for example, Urdea, Nature Biotechnology (1994), 12:926-928).
  • bDNA branched DNA
  • mRNA assays based on bDNA signal amplification are commercially available.
  • One such assay is the QuantiGene® Plex Gene Assay (Affymetrix, Santa Clara, CA).
  • Northern Blot and in situ hybridization may also be used to detect mRNAs. Suitable methods for performing Northern Blot and in situ hybridization are known in the art. Advanced sequencing methods can likewise be used as available.
  • mRNAs can be detected using Illumina ® Next Generation Sequencing (e.g. Sequencing-By-Synthesis or TruSeq methods, using, for example, the HiSeq, HiScan, GenomeAnalyzer, or MiSeq systems (Illumina, Inc., San Diego, CA)). mRNAs can also be detected using Ion Torrent Sequencing (Ion Torrent Systems, Inc., Gulliford, CT), or other suitable methods of semiconductor sequencing.
  • Illumina ® Next Generation Sequencing e.g. Sequencing-By-Synthesis or TruSeq methods, using, for example, the HiSeq, HiScan, GenomeAnalyzer, or MiSeq systems (Illumina, Inc., San Diego, CA)
  • Ion Torrent Sequencing Ion Torrent Systems, Inc., Gulliford, CT
  • the expression level is determined by metabolic imaging (see for example Yamashita T et al., Hepatology 2014, 60:1674-1685 or Ueno A et al., Journal of hepatology 2014, 61 :1080-1087).
  • Expression level of a gene may be expressed as absolute expression level or normalized expression level.
  • expression levels are normalized by correcting the absolute expression level of a gene by comparing its expression to the expression of a gene that is not a relevant for determining the response of antipsychotic treatment, e.g., a housekeeping gene that is constitutively expressed.
  • Suitable genes for normalization include housekeeping genes such as the actin gen Q ACTB, ribosomal 18S gene, GUSB, PGK1, TFRC, GAPDH, TBP and A IJ . This normalization allows the comparison of the expression level in one sample, e.g., a patient sample, to another sample, or between samples from different sources.
  • expression levels are normalized by correcting the absolute expression level of mRNAs by comparing its expression to the expression of a reference mRNA.
  • the subject as diagnosed with the method of the invention can be treated with an inhibitor of sPLA2 XIIA and/or with an inhibitor of its receptors (PLA2R1, syndecan and glypican).
  • the invention relates to a method for treating COPD in a subject in need thereof comprising a step of administrating to said subject a therapeutically amount of an inhibitor of sPLA2 XIIA and/or an inhibitor of sPLA2XIIA receptor.
  • the invention relates to an inhibitor of sPLA2 XIIA and/or an inhibitor of sPLA2XIIA receptor for use in the treatment of COPD in a subject in need thereof.
  • the inhibitor of sPLA2 XIIA and the inhibitor of sPLA2XIIA receptor are used as a combined preparation.
  • the invention relates to i) an inhibitor of sPLA2 XIIA and ii) an inhibitor of sPLA2XIIA receptor as combined preparation for simultaneous, separate or sequential use in the treatment of COPD in a subject in need thereof.
  • the invention relates to a method of treating COPD comprising the steps of: i) determining whether a subject suffers from COPD according to the method as described above and ii) administrating to said subject a therapeutically amount of inhibitor of sPLA2 XII A and/or an inhibitor of sPLA2XIIA receptor when it is concluded at step i) that the subject suffers from COPD.
  • the invention relates to an inhibitor of sPLA2 XII A and/or an inhibitor of sPLA2XIIA receptor for use in the treatment of COPD comprising the steps of: i) determining whether a subject suffers from COPD according to the method of the invention and ii) administrating to the subject a therapeutically amount of said inhibitor of sPLA2 Xlla when it is concluded at step i) that the subject suffers from COPD.
  • the inhibitor of sPLA2XIIA receptor is selected in the group consisting of inhibitor of PLA2R1, inhibitor of syndecan and inhibitor of glypican.
  • the inhibitor of sPLA2XIIA receptor is inhibitor of syndecan-4.
  • treatment refers to both prophylactic or preventive treatment as well as curative or disease modifying treatment, including treatment of subjects at risk of contracting the disease or suspected to have contracted the disease as well as subjects who are ill or have been diagnosed as suffering from a disease or medical condition, and includes suppression of clinical relapse.
  • the treatment may be administered to a subject having a medical disorder or who ultimately may acquire the disorder, in order to prevent, cure, delay the onset of, reduce the severity of, or ameliorate one or more symptoms of a disorder or recurring disorder, or in order to prolong the survival of a subject beyond that expected in the absence of such treatment.
  • therapeutic regimen is meant the pattern of treatment of an illness, e.g., the pattern of dosing used during therapy.
  • a therapeutic regimen may include an induction regimen and a maintenance regimen.
  • the phrase “induction regimen” or “induction period” refers to a therapeutic regimen (or the portion of a therapeutic regimen) that is used for the initial treatment of a disease.
  • the general goal of an induction regimen is to provide a high level of drug to a subject during the initial period of a treatment regimen.
  • An induction regimen may employ (in part or in whole) a "loading regimen", which may include administering a greater dose of the drug than a physician would employ during a maintenance regimen, administering a drug more frequently than a physician would administer the drug during a maintenance regimen, or both.
  • maintenance regimen refers to a therapeutic regimen (or the portion of a therapeutic regimen) that is used for the maintenance of a subject during treatment of an illness, e.g., to keep the subject in remission for long periods of time (months or years).
  • a maintenance regimen may employ continuous therapy (e.g., administering a drug at a regular intervals, e.g., weekly, monthly, yearly, etc.) or intermittent therapy (e.g., interrupted treatment, intermittent treatment, treatment at relapse, or treatment upon achievement of a particular predetermined criteria [e.g., disease manifestation, etc.]).
  • the term "therapeutically effective amount” refers to an amount effective, at dosages and for periods of time necessary, to achieve a desired therapeutic result.
  • a therapeutically effective amount of the immune checkpoint inhibitor of the present invention may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the immune checkpoint inhibitor of the present invention to elicit a desired response in the individual.
  • a therapeutically effective amount is also one in which any toxic or detrimental effects of the antibody or antibody portion are outweighed by the therapeutically beneficial effects.
  • the efficient dosages and dosage regimens for the immune checkpoint inhibitor of the present invention depend on the disease or condition to be treated and may be determined by the persons skilled in the art.
  • a physician having ordinary skill in the art may readily determine and prescribe the effective amount of the pharmaceutical composition required.
  • the physician could start doses of the immune checkpoint inhibitor of the present invention employed in the pharmaceutical composition at levels lower than that required achieving the desired therapeutic effect and gradually increasing the dosage until the desired effect is achieved.
  • a suitable dose of a composition of the present invention will be that amount of the compound, which is the lowest dose effective to produce a therapeutic effect according to a particular dosage regimen.
  • Such an effective dose will generally depend upon the factors described above.
  • a therapeutically effective amount for therapeutic use may be measured by its ability to stabilize the progression of disease.
  • the ability of a compound to inhibit cancer may, for example, be evaluated in an animal model system predictive of efficacy in human tumors.
  • a therapeutically effective amount of a therapeutic compound may decrease tumor size, or otherwise ameliorate symptoms in a subject.
  • One of ordinary skill in the art would be able to determine such amounts based on such factors as the subject's size, the severity of the subject's symptoms, and the particular composition or route of administration selected.
  • An exemplary, non-limiting range for a therapeutically effective amount of a inhibitor of the present invention is about 0.1-100 mg/kg, such as about 0.1-50 mg/kg, for example about 0.1-20 mg/kg, such as about 0.1-10 mg/kg, for instance about 0.5, about such as 0.3, about 1, about 3 mg/kg, about 5 mg/kg or about 8 mg/kg.
  • An exemplary, non-limiting range for a therapeutically effective amount of a inhibitor of the present invention is 0.02-100 mg/kg, such as about 0.02-30 mg/kg, such as about 0.05-10 mg/kg or 0.1-3 mg/kg, for example about 0.5-2 mg/kg.
  • Administration may e.g. be intravenous, intramuscular, intraperitoneal, or subcutaneous, and for instance administered proximal to the site of the target. Dosage regimens in the above methods of treatment and uses are adjusted to provide the optimum desired response (e.g., a therapeutic response). For example, a single bolus may be administered, several divided doses may be administered over time or the dose may be proportionally reduced or increased as indicated by the exigencies of the therapeutic situation.
  • the efficacy of the treatment is monitored during the therapy, e.g. at predefined points in time.
  • inhibitor of sPLA2 XIIA refers to a natural or synthetic compound that has a biological effect to inhibit the activity or the expression of sPLA2 XIIA. Such inhibitor inhibits the senescence of COPD cells that overexpress sPLA2 XIIA. Such inhibitor inhibits the senescence of COPD cells induced by sPLA2 XIIA.
  • the inhibitor of sPLA2 XIIA is a peptide, peptidomimetic, small organic molecule, antibody, aptamers, siRNA or antisense oligonucleotide.
  • peptidomimetic refers to a small protein-like chain designed to mimic a peptide.
  • the inhibitor of sPLA2 XIIA is a peptide.
  • the inhibitor of sPLA2 XIIA is a GAG-binding peptide.
  • GAG -binding peptide refers to a peptide which is able to bind to the GAG-binding site of sPLA2 XIIA,
  • the inhibitor of sPLA2 XIIA is a heparin-binding peptide
  • the inhibitor of sPLA2 XIIA is a peptide which block GAG-sPLA2 XII interaction.
  • the inhibitor of sPLA2 XIIA is an aptamer.
  • Aptamers are a class of molecule that represents an alternative to antibodies in term of molecular recognition.
  • Aptamers are oligonucleotide or oligopeptide sequences with the capacity to recognize virtually any class of target molecules with high affinity and specificity.
  • the inhibitor of sPLA2 XIIA is a small organic molecule.
  • small organic molecule refers to a molecule of a size comparable to those organic molecules generally used in pharmaceuticals. The term excludes biological macromolecules (e.g., proteins, nucleic acids, etc.). Preferred small organic molecules range in size up to about 5000 Da, more preferably up to 2000 Da, and most preferably up to about 1000 Da.
  • the inhibitor of sPLA2 XIIA is a glycosaminoglycan (GAG) or a glycosaminoglycan mimetic.
  • the inhibitor of sPLA2 XIIA is a heparin or heparin mimetics such as 2,3-O-desulfated heparin (ODSH) and hybrid heparin-like compound isolated from Litopenaeus vannamei shrimp 20-21
  • ODSH 2,3-O-desulfated heparin
  • GAG hybrid heparin-like compound isolated from Litopenaeus vannamei shrimp 20-21
  • GAG has its general meaning in the art and refers to a class of biomolecules expressed virtually on all mammalian cells and usually covalently attached to proteins, forming proteoglycans.
  • glycosaminoglycan mimetics has its general meaning in the art and refers to compounds that block GAG-protein interaction.
  • the glycosaminoglycan mimetic for use according to the invention can compete with heparan sulfate proteoglycans, i.e syndecan or glypican and block their interaction with sPLA2 XIIA.
  • GAG mimetics includes heparin, heparin mimetics such as 2,3-O-desulfated heparin (ODSH) and hybrid heparin-like compound isolated from Litopenaeus vannamei shrimp 20 21 ; fucoidane, chitine, chitosane modified polysaccharides, sulfated caffeic acid (CDS03), synthetically sulfated oligosaccharides, oligosaccharide-aglycone conjugates, non-carbohydrate-bases sulfated mimetics, muparfostat (PI-88); PG545; EP80061; SST0001 (roneparstat); fondaparinux (arixtra); Indraparinux; Idrabiotapariux; SR123781; AV5026 (semuloparin); M402
  • RGTA regenerating agents
  • heparin has its general meaning in the art and refers to glycosaminoglycan of formula C12H19NO20S3 which is used as an anticoagulant (blood thinner). Its CAS Number is 9005-49-6.
  • the inhibitor of sPLA2 XIIA is an antibody.
  • antibody is used in the broadest sense and specifically covers monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g. bispecific antibodies) formed from at least two intact antibodies, and antibody fragments so long as they exhibit the desired biological activity.
  • the term includes antibody fragments that comprise an antigen binding domain such as Fab', Fab, F(ab')2, single domain antibodies (DABs), TandAbs dimer, Fv, scFv (single chain Fv), dsFv, ds-scFv, Fd, linear antibodies, minibodies, diabodies, bispecific antibody fragments, bibody, tribody (scFv-Fab fusions, bispecific or trispecific, respectively); sc-diabody; kappa(lamda) bodies (scFv-CL fusions); BiTE (Bispecific T-cell Engager, scFv-scFv tandems to attract T cells); DVD-Ig (dual variable domain antibody, bispecific format); SIP (small immunoprotein, a kind of minibody); SMTP ("small modular immunopharmaceutical” scFv-Fc dimer; DART (ds-stabilized diabody "Dual Affinity ReTargeting"
  • Antibodies can be fragmented using conventional techniques. For example, F(ab')2 fragments can be generated by treating the antibody with pepsin. The resulting F(ab')2 fragment can be treated to reduce disulfide bridges to produce Fab' fragments. Papain digestion can lead to the formation of Fab fragments.
  • Fab, Fab' and F(ab')2, scFv, Fv, dsFv, Fd, dAbs, TandAbs, ds-scFv, dimers, minibodies, diabodies, bispecific antibody fragments and other fragments can also be synthesized by recombinant techniques or can be chemically synthesized. Techniques for producing antibody fragments are well known and described in the art. For example, each of Beckman et al, 2006; Holliger & Hudson, 2005; Le Gall et al, 2004; Reff & Heard, 2001 ; Reiter et al., 1996; and Young et al., 1995 further describe and enable the production of effective antibody fragments.
  • the antibody is a “chimeric” antibody as described in U.S. Pat. No. 4,816,567.
  • the antibody is a humanized antibody, such as described U.S. Pat. Nos. 6,982,321 and 7,087,409.
  • the antibody is a human antibody.
  • a “human antibody” such as described in US 6,075,181 and 6,150,584.
  • the antibody is a single domain antibody such as described in EP 0368 684, WO 06/030220 and WO 06/003388.
  • the inhibitor is a monoclonal antibody.
  • Monoclonal antibodies can be prepared and isolated using any technique that provides for the production of antibody molecules by continuous cell lines in culture. Techniques for production and isolation include but are not limited to the hybridoma technique, the human B- cell hybridoma technique and the EBV-hybridoma technique.
  • the inhibitor of sPLA2 XIIA is an intrabody having specificity for sPLA2 XIIA.
  • the term "intrabody” generally refer to an intracellular antibody or antibody fragment.
  • Antibodies in particular single chain variable antibody fragments (scFv), can be modified for intracellular localization. Such modification may entail for example, the fusion to a stable intracellular protein, such as, e.g., maltose binding protein, or the addition of intracellular trafficking/localization peptide sequences, such as, e.g., the endoplasmic reticulum retention.
  • the intrabody is a single domain antibody.
  • the antibody according to the invention is a single domain antibody.
  • the term “single domain antibody” (sdAb) or “VHH” refers to the single heavy chain variable domain of antibodies of the type that can be found in Camelid mammals which are naturally devoid of light chains. Such VHH are also called “nanobody®”. According to the invention, sdAb can particularly be llama sdAb.
  • the inhibitor of sPLA2 XIIA is a short hairpin RNA (shRNA), a small interfering RNA (siRNA) or an antisense oligonucleotide which inhibits the expression of sPLA2 XIIA.
  • the inhibitor of sPLA2 XIIA expression is siRNA.
  • a short hairpin RNA (shRNA) is a sequence of RNA that makes a tight hairpin turn that can be used to silence gene expression via RNA interference.
  • shRNA is generally expressed using a vector introduced into cells, wherein the vector utilizes the U6 promoter to ensure that the shRNA is always expressed.
  • siRNA small interfering RNA
  • siRNA RNA interference pathway whereby the siRNA interferes with the expression of a specific gene.
  • Anti-sense oligonucleotides include anti-sense RNA molecules and anti-sense DNA molecules, would act to directly block the translation of the targeted mRNA by binding thereto and thus preventing protein translation or increasing mRNA degradation, thus decreasing the level of the targeted protein, and thus activity, in a cell.
  • antisense oligonucleotides of at least about 15 bases and complementary to unique regions of the mRNA transcript sequence can be synthesized, e.g., by conventional phosphodiester techniques. Methods for using antisense techniques for specifically inhibiting gene expression of genes whose sequence is known are well known in the art (e.g. see U.S. Pat. Nos.
  • Antisense oligonucleotides, siRNAs, shRNAs of the invention may be delivered in vivo alone or in association with a vector.
  • a "vector" is any vehicle capable of facilitating the transfer of the antisense oligonucleotide, siRNA, shRNA or ribozyme nucleic acid to the cells and typically mast cells.
  • the vector transports the nucleic acid to cells with reduced degradation relative to the extent of degradation that would result in the absence of the vector.
  • the vectors useful in the invention include, but are not limited to, plasmids, phagemids, viruses, other vehicles derived from viral or bacterial sources that have been manipulated by the insertion or incorporation of the antisense oligonucleotide, siRNA, shRNA or ribozyme nucleic acid sequences.
  • Viral vectors are a preferred type of vector and include, but are not limited to nucleic acid sequences from the following viruses: retrovirus, such as moloney murine leukemia virus, harvey murine sarcoma virus, murine mammary tumor virus, and rous sarcoma virus; adenovirus, adeno-associated virus; SV40-type viruses; polyoma viruses; Epstein-Barr viruses; papilloma viruses; herpes virus; vaccinia virus; polio virus; and RNA virus such as a retrovirus.
  • retrovirus such as moloney murine leukemia virus, harvey murine sarcoma virus, murine mammary tumor virus, and rous sarcoma virus
  • adenovirus adeno-associated virus
  • SV40-type viruses polyoma viruses
  • Epstein-Barr viruses Epstein-Barr viruses
  • papilloma viruses herpes virus
  • vaccinia virus
  • NHEJ errorprone nonhomologous end-joining
  • HDR high-fidelity homology-directed repair
  • the endonuclease is CRISPR-cas.
  • CRISPR-cas has its general meaning in the art and refers to clustered regularly interspaced short palindromic repeats associated which are the segments of prokaryotic DNA containing short repetitions of base sequences.
  • the endonuclease is CRISPR-cas9 which is from Streptococcus pyogenes.
  • the CRISPR/Cas9 system has been described in US 8697359 B1 and US 2014/0068797. Originally an adaptive immune system in prokaryotes (Barrangou and Marraffmi, 2014), CRISPR has been recently engineered into a new powerful tool for genome editing. It has already been successfully used to target important genes in many cell lines and organisms, including human (Mali et al, 2013, Science, Vol. 339 : 823-826), bacteria (Fabre et al, 2014, PLoS Negl. Trop. Dis., Vol.
  • the endonuclease is CRISPR-Cpfl which is the more recently characterized CRISPR from Provotella and Francisella 1 (Cpfl) in Zetsche et al. (“Cpfl is a Single RNA-guided Endonuclease of a Class 2 CRISPR-Cas System (2015); Cell; 163, 1-13).
  • the term “inhibitor of PLA2R1” refers to a natural or synthetic compound that has a biological effect to inhibit the activity or the expression of PLA2R1. Such inhibitor can inhibit the senescence of COPD cells that overexpress sPLA2 XIIA.
  • the inhibitor of PLA2R1 is a short hairpin RNA (shRNA), a small interfering RNA (siRNA) or an antisense oligonucleotide which inhibits the expression of PLA2R1.
  • shRNA short hairpin RNA
  • siRNA small interfering RNA
  • antisense oligonucleotide which inhibits the expression of PLA2R1.
  • the inhibitor of sPLA2 XIIA expression is shRNA.
  • inhibitor of glypican refers to a natural or synthetic compound that has a biological effect to inhibit the activity or the expression of glypican.
  • inhibitor of syndecan refers to a natural or synthetic compound that has a biological effect to inhibit the activity or the expression of syndecan.
  • the inhibitor of glypican or syndecan is a synthetic xyloside such as b-D- xyloside; a heparan-sulfate lyase; a sulfotransferase inhibitor, a glycosyltransferase inhibitor; an antibody; an aptamers; siRNA or an antisense oligonucleotide.
  • the inhibitor of syndecan is heparin.
  • the inhibitor of sPLA2 XIIA and/or the inhibitor of sPLA2XIIA receptor is administered in combination with a classical treatment of COPD.
  • classical treatment refers to any compound, natural or synthetic, used for the treatment of COPD.
  • the classical treatment of COPD refers to p2-adrenergic agonists such as epinephrine ephedrine, albuterol, salbutamol, levalbuterol, pirbuterol, terbutaline, salmeterol, fomoterol, arfomoterol, bambuterol and indacaterol; anticholinergics such as ipratropium bromide, tiotropium, and aclidinoum; steroids such as fluticasone, budesonide, beclomethasone HFA, ciclesonide, mometasone; phosphodiesterase-4 inhibitors; theophylline; antibiotics and oxygen therapy.
  • the terms “combined treatment”, “combined therapy” or “therapy combination” refer to a treatment that uses more than one medication. The combined therapy may be dual therapy or bi-therapy.
  • the medications used in the combined treatment according to the invention are administered to the subject simultaneously, separately or sequentially.
  • administration simultaneously refers to administration of 2 active ingredients by the same route and at the same time or at substantially the same time.
  • administration separately refers to an administration of 2 active ingredients at the same time or at substantially the same time by different routes.
  • administration sequentially refers to an administration of 2 active ingredients at different times, the administration route being identical or different
  • the subject as diagnosed according to the invention can also be treated with a classical treatment of COPD.
  • the invention relates to a method of treating COPD in a subject in need thereof comprising a step of administrating to said subject a classical treatment of COPD.
  • the invention relates to a method of treating COPD in a subject in need thereof comprising the steps of: i) determining whether a subject suffers from COPD according to the method as described above and ii) administrating to said subject a classical treatment of COPD when it is concluded at step i) that the subject suffers from COPD
  • a fourth aspect of the invention relates to a therapeutic composition
  • a therapeutic composition comprising an inhibitor of sPLA2 XIIA according to the invention for use in the treatment of COPD in a subject as diagnosed according to the method as described above.
  • the invention relates to a therapeutic composition
  • a therapeutic composition comprising an inhibitor of sPLA2 XIIA according to the invention for use in the treatment of COPD in a subject with a bad prognosis as described above.
  • Any therapeutic agent of the invention may be combined with pharmaceutically acceptable excipients, and optionally sustained-release matrices, such as biodegradable polymers, to form therapeutic compositions.
  • “Pharmaceutically” or “pharmaceutically acceptable” refers to molecular entities and compositions that do not produce an adverse, allergic or other untoward reaction when administered to a mammal, especially a human, as appropriate.
  • a pharmaceutically acceptable carrier or excipient refers to a non-toxic solid, semi-solid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type.
  • compositions for example, the route of administration, the dosage and the regimen naturally depend upon the condition to be treated, the severity of the illness, the age, weight, and sex of the patient, etc.
  • compositions of the invention can be formulated for a topical, oral, intranasal, parenteral, intraocular, intravenous, intramuscular or subcutaneous administration and the like.
  • the pharmaceutical compositions contain vehicles which are pharmaceutically acceptable for a formulation capable of being injected.
  • vehicles which are pharmaceutically acceptable for a formulation capable of being injected.
  • These may be in particular isotonic, sterile, saline solutions (monosodium or disodium phosphate, sodium, potassium, calcium or magnesium chloride and the like or mixtures of such salts), or dry, especially freeze-dried compositions which upon addition, depending on the case, of sterilized water or physiological saline, permit the constitution of injectable solutions.
  • the doses used for the administration can be adapted as a function of various parameters, and in particular as a function of the mode of administration used, of the relevant pathology, or alternatively of the desired duration of treatment.
  • compositions include, e.g. tablets or other solids for oral administration; time release capsules; and any other form currently can be used.
  • Kit for yerformins the method according to the invention
  • the invention relates to a kit for performing the methods of the present invention, wherein said kit comprises means for measuring the expression level of soluble sPLA2 XIIA in a biological sample. More particularly, the kit comprising:
  • the at least one reagent can be, for example, a sPLA2 XIIA-specific antibody, a pair of sPLA2 XIIA-specific primers, etc.
  • FIGURES are a diagrammatic representation of FIGURES.
  • FIG. 1 Up-regulation of sPLA2 XIIA and PLA2R1 in COPD fibroblasts at senescent stages.
  • B Correlation between sPLA2 XIIA at passage 7 and FEV1/VC and FEV1.
  • C-E Correlation between sPLA2 XIIA at passage 7 and FEV1/VC and FEV1.
  • Figure 2 Up-regulation of heparan sulfate proteoglycans in SC-C and COPD fibroblasts at non-senescent and senescent stages. Abbreviations are the same as those described in Figure 1.
  • FIG. 3 sPLA2 XIIA induces the accelerated senescence of non-senescent fibroblasts. Abbreviations are the same as those described in Figure 1.
  • A Percentage of S A b- Gal-positive cells.
  • Immunocytochemical expression and quantification p21 (green fluorescence) after exposure to sPLA2 XIIA. Nuclei were counterstained with DAPI. Scale-bar 20 pm.
  • Bar graphs represent the percentage of fibroblasts expressing P-p53 or p21 after treatment with sPLA2 XIIA. * p ⁇ 0.05 sPLA2 XIIA vs. vehicle (DMSO). J p ⁇ 0.05 COPD vs. controls, £ p ⁇ 0.05 COPD vs. S- C.
  • B Bar graph of cells stained for SA b-Gal activity after pre-treatment with either heparanase or antibody against heparan sulfate proteoglycans (anti-HS) or pifithrin a (Pifia, 25 pM), and exposed to sPLA2 XIIA at 2 ng.ml 1 .
  • n 8 for NS-C, 15 for S-C and COPD.
  • Figure 4 sPLA2 XIIA activates MAPK pathway.
  • FIG. 5 sPLA2 XIIA induces ROS production. Abbreviations are the same as those described in Figure 1.
  • A. The pretreatment of cells by either scavengers of total ROS (NAC) or mitochondrial ROS (mitoquinol), or anti-HS or inhibitors of MAPK pathways or STAT3 inhibitors decreased the ROS production measured by DCFH-DA fluorescence, * p ⁇ 0.05 PGE2 vs. DMSO; t p ⁇ 0.05 COPD vs. controls, £ p ⁇ 0.05 COPD vs. S-C; $ p ⁇ 0.05 sPLA2 XIIA vs. sPLA2 XIIA + compounds.
  • sPLA2 XIIA activates the MIDAS.
  • Data are presented as mean ⁇ SEM
  • Figure 7 Expression of sPLA2 XIIA in the sera of patients. * p ⁇ 0.05 COPD patients versus non-smokers (NS-C) and smokers (S-C). Data are presented as mean ⁇ SEM
  • FIG. 8 sPLA2 XIIA induces ROS production. Abbreviations are the same as those described in Figure 1.
  • A Production of ROS was measured by DCFH-DA fluorescence and by analysis of HO-1 protein expression by western blot.
  • B The pretreatment of cells by either scavengers of total ROS (NAC) or mitochondrial ROS (mitoquinol), or anti-HS or syndecan-1 (SDC-1) or syndecan-4 (SDC-4) or inhibitors of MAPK pathways (SB202190, U 0160) or inhibitor of STAT3 pathways (S31201) decreased the ROS production measured by DCFH- DA fluorescence, * p ⁇ 0.05 PGE2 vs.
  • sPLA2 XIIA and inhibitors such as U0126, SB202190, pifithrin-a, N acethyl cysteine, Mitoquinol, S31201 were purchased from Abeam and Sigma (Saint Quentin Fallavier, France) respectively.
  • Lung fibroblasts were isolated from lung tissue from patients undergoing resective surgery for pulmonary carcinoma. Pleura- free parenchymal specimens were excised after careful macroscopic evaluation, from peripheral areas of the lobe as far away as possible from the tumor site. Lung fibroblasts were obtained by the explant method (17).
  • DMEM Dulbecco’s modified Eagle’s medium
  • FBS heat-inactivated fetal bovine serum
  • PHA Heat-inactivated fetal bovine serum
  • Isolated cells were characterized as fibroblasts by morphological appearance and expression pattern of specific proteins by immunocytochemistry.
  • Rate of cell proliferation was assessed by measuring cumulative population doubling levels (PDLs). Briefly, cells were seeded at 100.000 cells per 25 cm 2 , grown for 1 week, harvested and seeded again until loss of cellular growth. PDLs calculated at each passage were summed to obtain a cumulative PDL.
  • Fibroblasts isolated from non-smokers, smokers and COPD patients were used at non- senescent passage (passage 3). We checked that the concentration of all compounds used in this section didn’t alter the viability of cells by using MTT and LDH assays (data not shown).
  • Fibroblasts were exposed either to sPLA2 XIIA (0.5, 2 and 50 ng/ml) for 24 h or pre treated with different inhibitors before be treated with sPLA2 XIIA.
  • fibroblasts were pre-exposed to either heparanase (I and III) or anti-heparan sulfate for 2h.
  • NAC 5 mM
  • MITOQ 25 nM
  • fibroblasts were pre-exposed to pifithrin-a (25 mM), a transcriptional inhibitor of phospho-p53 activity (ref) for 24 hours, or inhibitors of ERK (U0126, 10 pM) or P38 (SB202190,10 pM) and treated with sPLA2XIIA for one more day.
  • Pulmonary fibroblasts were cultivated in an 8-well glass slide chamber. After exposure to either sPLA2 XIIA or sPLA2 XIIA and different inhibitors, staining for SA b-Gal activity (Ozyme, Saint-Quentin-en-Yvelines, France) was performed as described (18). Cells were fixed in 2% formaldehyde and 0.2% glutaraldehyde for 10 minutes at room temperature.
  • the slides were then rinsed with PBS and incubated with an SA b-Gal staining solution containing 40 mM sodium citrate (pH 6), 150 mM, NaCl, 5 mM potassium ferri cyanide, 5 mM potassium ferrocyanide, 2 mM MgCk and 1 mg/ml 5 bromo-4-chloro-3-indolyl ⁇ -D-galactoside. Positive cells stained with blue were counted under visible light by two independent observers.
  • Lung fibroblasts samples were lysed on ice in a lysis buffer (10 mM Tris-HCl, pH 6.8, 150 mM NaCl, 10 mM Hepes, Saccharose 500 mM, Na2 EDTA 1 mM, 1.0% NP-40, 10% anti protease and 1% anti-phosphatase).
  • the protein concentration of these cell extracts was quantified using Bradford protein assay (Bio-Rad Laboratories, Mame-La-Coquette, France). An equal amount of protein (30 pg/lane) from each cell extract was resolved on a 10% or 12% SDS-PAGE gel.
  • VDF Immuno-Blot polyvinylidenediflouride
  • the membranes were blocked with TBS-T blocking buffer (10 % milk in 25 mM, Tris-HCl, pH 7.4, 3 mM; KC1, 140 mM; NaCl, and 0.05% Tween) and subsequently probed with following primary antibodies either overnight at 4°C: rabbit polyclonal pi 6, mouse monoclonal p21 (1:200, Santa Cruz Biotechnology, Heidelberg, Germany), or syndecan 1, 4 (Abeam, Cambridge, UK) or glypican 1, 4, P-ERK, ERK, P-p38, p38, p-AMPK, AMPK, SIRT3, P- NFKB, NKFB.
  • TBS-T blocking buffer 10 % milk in 25 mM, Tris-HCl, pH 7.4, 3 mM; KC1, 140 mM; NaCl, and 0.05% Tween
  • immunoblots were then incubated with an appropriate peroxidase-conjugated secondary antibody (GE Healthcare Europe, Orsay, France) for 1 h at room temperature. After three washes with TBS-T, immunoblots were detected using the ECL Western Blotting Detection Reagents (GE Healthcare Europe, Orsay, France) and recorded by exposure of the immunoblots to an X-ray film (Sigma, Saint Quentin Fallavier, France). The results were expressed as a ratio to b-actin expression. With this aim, immunoblots were incubated with b-actin primary antibody for 30 minutes at room temperature (Sigma, Saint Quentin Fallavier, France).
  • Fibroblasts were cultivated in 8-well glass slide chamber. After treatments, cells were fixed in either 4% paraformaldehyde or methanol for 15 min at 4°C. Cells were permeabilized with 0.05 % Triton x-100 (Sigma, Saint Quentin Fallavier, France) for 15 min, washed and blocked in 2% BSA at ambient temperature. Cells were incubated with following primary antibodies overnight at 4°C: rabbit polyclonal phospho (serine 15)-p53 (1:500, Abeam), mouse monoclonal p21 (1:50, Santa Cruz Biotechnology, Heidelberg, Germany).
  • Fluorescence signal was detected by using a goat anti- mouse secondary antibody (1:500, conjugated with Alexa 594, Invitrogen, Cergy-Pontoise, France). The slides were mounted by using prolong DAPI (Invitrogen, Cergy-Pontoise, France). A fluorescence microscope coupled to a digital camera utilizing axiovision software was used to view and acquire images (Zeiss, Jena, Germany). Quantification was performed by using Image J software (NIH, MD, USA). sPLA2 XIIA assay
  • sPLA2 XIIA concentration of sPLA2 XIIA was measured in conditioned medium collected at passage 3 and 7.
  • sPLA2 XIIA was quantified using the quantitative sandwich enzyme immunoassay technique (Cusabio, foumisseur Clini sciences, France) according to the manufacturer's instructions (Bertin Pharma, Montigny-Le-Bretonneux, France). Concentration (pg/ml) was determined by generating a standard curve with known concentrations of sPLA2 XIIA and normalized with the number of cells used to generate the conditioned media.
  • Endogenous ROS were quantified by oxidation of 2’, 7’ dichlorofluorescin diacetate (DCFH2-DA) into 2’, 7’ dichlorofluorescin (Thermofischer, France). Briefly, cells were cultivated in 6 wells culture plates and treated with either sPLA2 XIIA alone or sPLA2 XIIA with NAC or MitoQ. Cells were also treated with 250 mM H2O2 as a positive control (data not shown). Cells were incubated with 20 pM DCFH2-DA for 30 min at 37°C and fluorescence recorded for 45 minutes.
  • DCFH2-DA dichlorofluorescin diacetate
  • sPLA2 which are surrogated in the lung such as sPLA2 IB, IIA, IID, XIIA, V and X in pulmonary fibroblasts from non- smokers (NS-C), smokers (S- C) and COPD patients at non-senescent and senescent stages (data not shown).
  • NS-C non- smokers
  • S- C smokers
  • COPD patients at non-senescent and senescent stages
  • sPLA2 XIIA mRNA expression was significantly higher in fibroblasts from COPD patients as compared with NS-C groups at passage 3 ( Figure 1A).
  • Figure 1A At passage 7, in COPD fibroblasts, secreted sPLA2 XIIA levels and its mRNA expression were significantly higher as compared with passage 3 and versus NS-C and S-C groups ( Figure 1 A).
  • sPLA2s act through specific receptors, named PLA2R1 and heparan sulfate proteoglycan (syndecan and glypican).
  • PLA2R1 heparan sulfate proteoglycan
  • mRNA expression of PLA2R1 was significantly higher in S-C and COPD fibroblasts as compared to NS-C groups ( Figure 1C), and this difference was maintained at passage 7.
  • its mRNA expression was significantly higher as compared with passage 3 in S-C and COPD fibroblasts.
  • mRNA expression of glypican 1 in COPD fibroblasts were significantly higher as compared with passage 3 and versus controls groups mRNA expression of syndecan 4 in COPD and S-C fibroblasts were significantly higher compared with NS-C.
  • Lung fibroblasts were exposed to three doses of sPLA2 XIIA: 0.5; 2 and 50 ng/ml. Twenty-four hours incubation of non-senescent fibroblasts with sPLA2 XIIA at the dose of 0.5 and 2 ng/ml induced a dose-response increase in the percentage of cells expressing SA b-gal, P-p53, p21 and pl6 in S-C and COPD fibroblasts ( Figure 3A). These inductions were significantly higher in COPD compared with control fibroblasts whereas no significant effects were detected in NS-C fibroblasts at the dose of 0.5 ng/ml.
  • fibroblasts from S-C and COPD patients were treated with either shRNA PLA2R1 or heparanase I and III to cleave the heparan sulfate chains on proteoglycans.
  • the exposure to heparanase significantly reduced sPLA2 XIIA-induced SA b-gal and p21 expression in COPD fibroblasts ( Figure 3B-C).
  • Figure 3B-C an anti-heparan sulfate antibody
  • PLA2R1 is known to activate several signaling pathways such as MAPK, JAK/STAT (15, 16), we investigated the time-course (from 5 minutes to 2 hours) protein expression level of MAPK and JAK/STAT pathways after treatment with sPLA2 XIIA at 2 ng/ml.
  • the protein expressions of P-ERK, P- p38 and P Tyr707 STAT3 increased after 5 minutes of treatment in S-C and COPD fibroblasts. However, these effects were transient in S- C fibroblasts whereas they were maintained in COPD fibroblasts (data not shown).
  • activated STAT3 can exert its transcriptional activity after a second phosphorylation (ref).
  • MIDAS is characterized by a lack of several cytokines including IL-6, IL-8 and IL-1 and by the activation of AMPK-p53 pathway and the expression of TNFa, CCL27 and IL-10.
  • cytokines including IL-6, IL-8 and IL-1
  • AMPK-p53 pathway the activation of AMPK-p53 pathway and the expression of TNFa, CCL27 and IL-10.
  • AMPK is also known to be involved in the activation of P-p53. Indeed, the blockage of AMPK with compound C lead to a decrease of the phosphorylation of p53 induced by sPLA2 XIIA, showing its role in the senescence (data not shown). IL-10 and TNFa were increased after an exposure to sPLA2 XIIA and this increase was higher in COPD as compared to control fibroblasts ( Figure 6). In interesting way, the pifithrin a abolished the effects of sPLA2 XIIA.
  • the level of sPLA2 XIIA was significantly higher in the sera of COPD patients than the one of controls, suggesting that this protein could be a potential marker of this pathology and a potential target for therapeutics treatments.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La bronchopneumopathie chronique obstructive (BPCO), une maladie associée au tabagisme, est l'une des causes principales de décès dans le monde, et représente une charge de soins de santé globale significative. Les inventeurs ont précédemment démontré que PGE2, un médiateur lipidique dérivé du métabolisme de la phospholipase A2 (PLA2) et la cyclo-oxygénase (COX), participent à la propagation de la sénescence dans les fibroblastes pulmonaires de la BPCO. Ils ont également approfondi l'étude de ces voies de signalisation en se focalisant sur la PLA2 sécrétée (sPLA2) et plus particulièrement sur ses Isoformes catalytiquement actives XIIA et ses récepteurs (PLA2R1 et les protéoglycanes de sulfate d'héparane). Leurs résultats indiquent une régulation positive de la sPLA2XIIA et de ses récepteurs dans les fibroblastes dans la BPCO. De plus, il a été découvert qu'une seule exposition de sPLA2XIIA induit une sénescence (par l'intermédiaire de protéoglycanes de sulfate d'héparane, ERK, p38, STAT3, ROS, AMPK/p53/p21) et que les fibroblastes dans la BPCO sont significativement plus sensibles à ces effets que des cellules témoins. Pris ensemble, ces données définissent la sPLA2XIIA en tant que biomarqueur circulant pour la BPCO et établissent une exigence d'inhibition de sPLA2 XIIA pour le traitement ou la prévention de la BPCO.
PCT/EP2020/077267 2019-09-30 2020-09-29 Procédé et composition pour diagnostiquer une maladie pulmonaire chronique obstructive WO2021063968A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19306235.3 2019-09-30
EP19306235 2019-09-30

Publications (1)

Publication Number Publication Date
WO2021063968A1 true WO2021063968A1 (fr) 2021-04-08

Family

ID=68281370

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2020/077267 WO2021063968A1 (fr) 2019-09-30 2020-09-29 Procédé et composition pour diagnostiquer une maladie pulmonaire chronique obstructive

Country Status (1)

Country Link
WO (1) WO2021063968A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117269287A (zh) * 2023-11-20 2023-12-22 中国计量科学研究院 一种喷墨进样-毛细管电泳-质谱联用装置及工作方法

Citations (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4774339A (en) 1987-08-10 1988-09-27 Molecular Probes, Inc. Chemically reactive dipyrrometheneboron difluoride dyes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0368684A1 (fr) 1988-11-11 1990-05-16 Medical Research Council Clonage de séquences d'immunoglobulines de domaines variables.
EP0404097A2 (fr) 1989-06-22 1990-12-27 BEHRINGWERKE Aktiengesellschaft Récepteurs mono- et oligovalents, bispécifiques et oligospécifiques, ainsi que leur production et application
US5132432A (en) 1989-09-22 1992-07-21 Molecular Probes, Inc. Chemically reactive pyrenyloxy sulfonic acid dyes
US5187288A (en) 1991-05-22 1993-02-16 Molecular Probes, Inc. Ethenyl-substituted dipyrrometheneboron difluoride dyes and their synthesis
WO1993011161A1 (fr) 1991-11-25 1993-06-10 Enzon, Inc. Proteines multivalentes de fixation aux antigenes
US5248782A (en) 1990-12-18 1993-09-28 Molecular Probes, Inc. Long wavelength heteroaryl-substituted dipyrrometheneboron difluoride dyes
US5262357A (en) 1991-11-22 1993-11-16 The Regents Of The University Of California Low temperature thin films formed from nanocrystal precursors
US5274113A (en) 1991-11-01 1993-12-28 Molecular Probes, Inc. Long wavelength chemically reactive dipyrrometheneboron difluoride dyes and conjugates
US5338854A (en) 1991-02-13 1994-08-16 Molecular Probes, Inc. Fluorescent fatty acids derived from dipyrrometheneboron difluoride dyes
US5433896A (en) 1994-05-20 1995-07-18 Molecular Probes, Inc. Dibenzopyrrometheneboron difluoride dyes
US5505928A (en) 1991-11-22 1996-04-09 The Regents Of University Of California Preparation of III-V semiconductor nanocrystals
US5571018A (en) 1994-11-23 1996-11-05 Motorola, Inc. Arrangement for simulating indirect fire in combat training
US5690807A (en) 1995-08-03 1997-11-25 Massachusetts Institute Of Technology Method for producing semiconductor particles
US5696157A (en) 1996-11-15 1997-12-09 Molecular Probes, Inc. Sulfonated derivatives of 7-aminocoumarin
US5800996A (en) 1996-05-03 1998-09-01 The Perkin Elmer Corporation Energy transfer dyes with enchanced fluorescence
US5830912A (en) 1996-11-15 1998-11-03 Molecular Probes, Inc. Derivatives of 6,8-difluoro-7-hydroxycoumarin
US5866366A (en) 1997-07-01 1999-02-02 Smithkline Beecham Corporation gidB
WO1999026299A1 (fr) 1997-11-13 1999-05-27 Massachusetts Institute Of Technology Materiaux chromo-selectifs hautement luminescents
US5981732A (en) 1998-12-04 1999-11-09 Isis Pharmaceuticals Inc. Antisense modulation of G-alpha-13 expression
US5990479A (en) 1997-11-25 1999-11-23 Regents Of The University Of California Organo Luminescent semiconductor nanocrystal probes for biological applications and process for making and using such probes
US6046321A (en) 1999-04-09 2000-04-04 Isis Pharmaceuticals Inc. Antisense modulation of G-alpha-i1 expression
US6048616A (en) 1993-04-21 2000-04-11 Philips Electronics N.A. Corp. Encapsulated quantum sized doped semiconductor particles and method of manufacturing same
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6107091A (en) 1998-12-03 2000-08-22 Isis Pharmaceuticals Inc. Antisense inhibition of G-alpha-16 expression
US6114038A (en) 1998-11-10 2000-09-05 Biocrystal Ltd. Functionalized nanocrystals and their use in detection systems
US6130101A (en) 1997-09-23 2000-10-10 Molecular Probes, Inc. Sulfonated xanthene derivatives
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6207392B1 (en) 1997-11-25 2001-03-27 The Regents Of The University Of California Semiconductor nanocrystal probes for biological applications and process for making and using such probes
US6225198B1 (en) 2000-02-04 2001-05-01 The Regents Of The University Of California Process for forming shaped group II-VI semiconductor nanocrystals, and product formed using process
US6274323B1 (en) 1999-05-07 2001-08-14 Quantum Dot Corporation Method of detecting an analyte in a sample using semiconductor nanocrystals as a detectable label
US6306736B1 (en) 2000-02-04 2001-10-23 The Regents Of The University Of California Process for forming shaped group III-V semiconductor nanocrystals, and product formed using process
US6365354B1 (en) 2000-07-31 2002-04-02 Isis Pharmaceuticals, Inc. Antisense modulation of lysophospholipase I expression
US6410323B1 (en) 1999-08-31 2002-06-25 Isis Pharmaceuticals, Inc. Antisense modulation of human Rho family gene expression
US6500622B2 (en) 2000-03-22 2002-12-31 Quantum Dot Corporation Methods of using semiconductor nanocrystals in bead-based nucleic acid assays
US6566131B1 (en) 2000-10-04 2003-05-20 Isis Pharmaceuticals, Inc. Antisense modulation of Smad6 expression
US6566135B1 (en) 2000-10-04 2003-05-20 Isis Pharmaceuticals, Inc. Antisense modulation of caspase 6 expression
US6602671B1 (en) 1998-09-18 2003-08-05 Massachusetts Institute Of Technology Semiconductor nanocrystals for inventory control
US6649138B2 (en) 2000-10-13 2003-11-18 Quantum Dot Corporation Surface-modified semiconductive and metallic nanoparticles having enhanced dispersibility in aqueous media
US6682596B2 (en) 2000-12-28 2004-01-27 Quantum Dot Corporation Flow synthesis of quantum dot nanocrystals
US6689338B2 (en) 2000-06-01 2004-02-10 The Board Of Regents For Oklahoma State University Bioconjugates of nanoparticles as radiopharmaceuticals
US6709929B2 (en) 2001-06-25 2004-03-23 North Carolina State University Methods of forming nano-scale electronic and optoelectronic devices using non-photolithographically defined nano-channel templates
US6716979B2 (en) 2000-08-04 2004-04-06 Molecular Probes, Inc. Derivatives of 1,2-dihydro-7-hydroxyquinolines containing fused rings
US6815064B2 (en) 2001-07-20 2004-11-09 Quantum Dot Corporation Luminescent nanoparticles and methods for their preparation
US6855202B2 (en) 2001-11-30 2005-02-15 The Regents Of The University Of California Shaped nanocrystal particles and methods for making the same
US6982321B2 (en) 1986-03-27 2006-01-03 Medical Research Council Altered antibodies
WO2006003388A2 (fr) 2004-06-30 2006-01-12 Domantis Limited Compositions et procedes pour le traitement de troubles inflammatoires
WO2006030220A1 (fr) 2004-09-17 2006-03-23 Domantis Limited Compositions monovalentes pour la liaison au cd40l et procedes d'utilisation
US7087409B2 (en) 1997-12-05 2006-08-08 The Scripps Research Institute Humanization of murine antibody
US20090230325A1 (en) * 2002-02-13 2009-09-17 Wisconsin Alumni Research Foundation Method For Measuring Activity of a Specific Fraction of Albumin
WO2010085586A1 (fr) * 2009-01-23 2010-07-29 The Brigham And Women's Hospital, Inc. Biomarqueurs de phospholipase a2 sécrétée pour l'arthrite
US20140031252A1 (en) * 2009-06-24 2014-01-30 Board Of Regents Of The University Of Nebraska Compositions and methods for the diagnosis and treatment of inlammatory disorders and fibrotic disease
US20140068797A1 (en) 2012-05-25 2014-03-06 University Of Vienna Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
US20140135302A1 (en) * 2012-11-07 2014-05-15 Somalogic, Inc. Chronic obstructive pulmonary disease (copd) biomarkers and uses thereof

Patent Citations (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6982321B2 (en) 1986-03-27 2006-01-03 Medical Research Council Altered antibodies
US4774339A (en) 1987-08-10 1988-09-27 Molecular Probes, Inc. Chemically reactive dipyrrometheneboron difluoride dyes
EP0368684A1 (fr) 1988-11-11 1990-05-16 Medical Research Council Clonage de séquences d'immunoglobulines de domaines variables.
EP0404097A2 (fr) 1989-06-22 1990-12-27 BEHRINGWERKE Aktiengesellschaft Récepteurs mono- et oligovalents, bispécifiques et oligospécifiques, ainsi que leur production et application
US5132432A (en) 1989-09-22 1992-07-21 Molecular Probes, Inc. Chemically reactive pyrenyloxy sulfonic acid dyes
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5248782A (en) 1990-12-18 1993-09-28 Molecular Probes, Inc. Long wavelength heteroaryl-substituted dipyrrometheneboron difluoride dyes
US5338854A (en) 1991-02-13 1994-08-16 Molecular Probes, Inc. Fluorescent fatty acids derived from dipyrrometheneboron difluoride dyes
US5187288A (en) 1991-05-22 1993-02-16 Molecular Probes, Inc. Ethenyl-substituted dipyrrometheneboron difluoride dyes and their synthesis
US5274113A (en) 1991-11-01 1993-12-28 Molecular Probes, Inc. Long wavelength chemically reactive dipyrrometheneboron difluoride dyes and conjugates
US5451663A (en) 1991-11-01 1995-09-19 Molecular Probes, Inc. Long wavelength chemically reactive dipyrrometheneboron difluoride dyes and conjugates
US5262357A (en) 1991-11-22 1993-11-16 The Regents Of The University Of California Low temperature thin films formed from nanocrystal precursors
US5505928A (en) 1991-11-22 1996-04-09 The Regents Of University Of California Preparation of III-V semiconductor nanocrystals
WO1993011161A1 (fr) 1991-11-25 1993-06-10 Enzon, Inc. Proteines multivalentes de fixation aux antigenes
US6048616A (en) 1993-04-21 2000-04-11 Philips Electronics N.A. Corp. Encapsulated quantum sized doped semiconductor particles and method of manufacturing same
US5433896A (en) 1994-05-20 1995-07-18 Molecular Probes, Inc. Dibenzopyrrometheneboron difluoride dyes
US5571018A (en) 1994-11-23 1996-11-05 Motorola, Inc. Arrangement for simulating indirect fire in combat training
US5690807A (en) 1995-08-03 1997-11-25 Massachusetts Institute Of Technology Method for producing semiconductor particles
US5800996A (en) 1996-05-03 1998-09-01 The Perkin Elmer Corporation Energy transfer dyes with enchanced fluorescence
US5696157A (en) 1996-11-15 1997-12-09 Molecular Probes, Inc. Sulfonated derivatives of 7-aminocoumarin
US5830912A (en) 1996-11-15 1998-11-03 Molecular Probes, Inc. Derivatives of 6,8-difluoro-7-hydroxycoumarin
US5866366A (en) 1997-07-01 1999-02-02 Smithkline Beecham Corporation gidB
US6130101A (en) 1997-09-23 2000-10-10 Molecular Probes, Inc. Sulfonated xanthene derivatives
WO1999026299A1 (fr) 1997-11-13 1999-05-27 Massachusetts Institute Of Technology Materiaux chromo-selectifs hautement luminescents
US6207392B1 (en) 1997-11-25 2001-03-27 The Regents Of The University Of California Semiconductor nanocrystal probes for biological applications and process for making and using such probes
US5990479A (en) 1997-11-25 1999-11-23 Regents Of The University Of California Organo Luminescent semiconductor nanocrystal probes for biological applications and process for making and using such probes
US6927069B2 (en) 1997-11-25 2005-08-09 The Regents Of The University Of California Organo luminescent semiconductor nanocrystal probes for biological applications and process for making and using such probes
US7087409B2 (en) 1997-12-05 2006-08-08 The Scripps Research Institute Humanization of murine antibody
US6602671B1 (en) 1998-09-18 2003-08-05 Massachusetts Institute Of Technology Semiconductor nanocrystals for inventory control
US6114038A (en) 1998-11-10 2000-09-05 Biocrystal Ltd. Functionalized nanocrystals and their use in detection systems
US6107091A (en) 1998-12-03 2000-08-22 Isis Pharmaceuticals Inc. Antisense inhibition of G-alpha-16 expression
US5981732A (en) 1998-12-04 1999-11-09 Isis Pharmaceuticals Inc. Antisense modulation of G-alpha-13 expression
US6046321A (en) 1999-04-09 2000-04-04 Isis Pharmaceuticals Inc. Antisense modulation of G-alpha-i1 expression
US6274323B1 (en) 1999-05-07 2001-08-14 Quantum Dot Corporation Method of detecting an analyte in a sample using semiconductor nanocrystals as a detectable label
US6410323B1 (en) 1999-08-31 2002-06-25 Isis Pharmaceuticals, Inc. Antisense modulation of human Rho family gene expression
US6306736B1 (en) 2000-02-04 2001-10-23 The Regents Of The University Of California Process for forming shaped group III-V semiconductor nanocrystals, and product formed using process
US6225198B1 (en) 2000-02-04 2001-05-01 The Regents Of The University Of California Process for forming shaped group II-VI semiconductor nanocrystals, and product formed using process
US6500622B2 (en) 2000-03-22 2002-12-31 Quantum Dot Corporation Methods of using semiconductor nanocrystals in bead-based nucleic acid assays
US20030165951A1 (en) 2000-03-22 2003-09-04 Quantum Dot Corporation Methods of using semiconductor nanocrystals in bead-based nucleic acid assays
US6689338B2 (en) 2000-06-01 2004-02-10 The Board Of Regents For Oklahoma State University Bioconjugates of nanoparticles as radiopharmaceuticals
US6365354B1 (en) 2000-07-31 2002-04-02 Isis Pharmaceuticals, Inc. Antisense modulation of lysophospholipase I expression
US6716979B2 (en) 2000-08-04 2004-04-06 Molecular Probes, Inc. Derivatives of 1,2-dihydro-7-hydroxyquinolines containing fused rings
US6566131B1 (en) 2000-10-04 2003-05-20 Isis Pharmaceuticals, Inc. Antisense modulation of Smad6 expression
US6566135B1 (en) 2000-10-04 2003-05-20 Isis Pharmaceuticals, Inc. Antisense modulation of caspase 6 expression
US6649138B2 (en) 2000-10-13 2003-11-18 Quantum Dot Corporation Surface-modified semiconductive and metallic nanoparticles having enhanced dispersibility in aqueous media
US6682596B2 (en) 2000-12-28 2004-01-27 Quantum Dot Corporation Flow synthesis of quantum dot nanocrystals
US6709929B2 (en) 2001-06-25 2004-03-23 North Carolina State University Methods of forming nano-scale electronic and optoelectronic devices using non-photolithographically defined nano-channel templates
US6914256B2 (en) 2001-06-25 2005-07-05 North Carolina State University Optoelectronic devices having arrays of quantum-dot compound semiconductor superlattices therein
US6815064B2 (en) 2001-07-20 2004-11-09 Quantum Dot Corporation Luminescent nanoparticles and methods for their preparation
US6855202B2 (en) 2001-11-30 2005-02-15 The Regents Of The University Of California Shaped nanocrystal particles and methods for making the same
US20090230325A1 (en) * 2002-02-13 2009-09-17 Wisconsin Alumni Research Foundation Method For Measuring Activity of a Specific Fraction of Albumin
WO2006003388A2 (fr) 2004-06-30 2006-01-12 Domantis Limited Compositions et procedes pour le traitement de troubles inflammatoires
WO2006030220A1 (fr) 2004-09-17 2006-03-23 Domantis Limited Compositions monovalentes pour la liaison au cd40l et procedes d'utilisation
WO2010085586A1 (fr) * 2009-01-23 2010-07-29 The Brigham And Women's Hospital, Inc. Biomarqueurs de phospholipase a2 sécrétée pour l'arthrite
US20140031252A1 (en) * 2009-06-24 2014-01-30 Board Of Regents Of The University Of Nebraska Compositions and methods for the diagnosis and treatment of inlammatory disorders and fibrotic disease
US20140068797A1 (en) 2012-05-25 2014-03-06 University Of Vienna Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
US20140135302A1 (en) * 2012-11-07 2014-05-15 Somalogic, Inc. Chronic obstructive pulmonary disease (copd) biomarkers and uses thereof
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products

Non-Patent Citations (55)

* Cited by examiner, † Cited by third party
Title
"Uniprot", Database accession no. Q9Y625
ACOSTA JCBANITO AWUESTEFELD TGEORGILIS AJANICH PMORTON JPATHINEOS DKANG TWLASITSCHKA FANDRULIS M: "A complex secretory program orchestrated by the inflammasome controls paracrine senescence", NAT.CELL.BIOL., vol. 5, no. 8, 2013, pages 978 - 90
ADRIANA BRITOROMULO CAVALCANTERENAN CAVALHEIROLAIS PALHARESLEONARDO NOBREGIULIANNA ANDRADEHELENA NADERMARCELO LIMASUELY CHAVANTE: "Anti-IIa activity and antitumor properties of a hybrid heparin/heparan sulfate-like compound from Litopenaeus vannamei shrimp", INT J BIOL MACROMOL, vol. 118, 2018, pages 1470 - 1478
AMSELLEM, V.GARY-BOBO, G.MARCOS, E.MAITRE, B.CHAAR, V.VALIDIRE, P.ADNOT, S.: "Telomere dysfunction causes sustained inflammation in chronic obstructive pulmonary disease", AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, vol. 184, 2011, pages 1358 - 1366, XP055175613, DOI: 10.1164/rccm.201105-0802OC
AUGERT A ET AL.: "PLA2R1 kills cancer cells by inducing mitochondrial stress", FREE RADIC BIOL MED, vol. 65, 2013, pages 969 - 77
BANDURA DR, ANALYTICAL CHEMISTRY, 2009
BRUCHEZ ET AL., SCIENCE, vol. 281, 1998, pages 20132016 - 2018
CAMPISI, J.: "Senescent cells, tumor suppression, and organismal aging: Good citizens, bad neighbors", CELL, vol. 120, 2005, pages 513 - 522, XP055008918, DOI: 10.1016/j.cell.2005.02.003
CHEMICAL ABSTRACTS, Columbus, Ohio, US; abstract no. 9005-49-6
CHENG ET AL., ANGEW CHEM. INT. ED. ENGL., vol. 48, no. 18, 2009, pages 3268 - 72
COPPE JPDESPREZ PYKRTOLICA ACAMPISI J.: "The senescence-associated secretory phenotype: the dark side of tumor suppression", ANNU REV PATHOL, vol. 5, 2010, pages 99 - 118
DAGOUASSAT, M.GAGLIOLO, J. M.CHRUSCIEL, S.BOURIN, M. C.DUPREZ, C.CARAMELLE, P.BOCZKOWSKI, J.: "The cyclooxygenase-2-prostaglandin E2 pathway maintains senescence of chronic obstructive pulmonary disease fibroblasts", AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, vol. 187, 2013, pages 703 - 714
DAVID CL LAM ET AL: "S-maltoheptaose targets syndecan-bound effectors to reduce smoking-related neutrophilic inflammation", SCIENTIFIC REPORTS, vol. 5, no. 1, 10 August 2015 (2015-08-10), XP055668869, DOI: 10.1038/srep12945 *
DICARLO ET AL., NUCLEIC ACIDS RES., vol. 41, 2013, pages 4336 - 4343
DIMRI G.PLEE XBASILE GACOSTA MSCOTT GROSKELLEY CMEDRANO E.ELINSKENS MRUBERLJ IPEREIRA-SMITH O.A: "A biomarker that identifies senescent human cells in culture and in aging skin in vivo", NATL.ACAD.SCI., vol. 92, 1995, pages 9363 - 67, XP009065201, DOI: 10.1073/pnas.92.20.9363
FABRE ET AL., PLOS NEGL. TROP. DIS., vol. 8, 2014, pages e2671
GALLIEN DOMON: "Detection and quantification of proteins in clinical samples using high resolution mass spectrometry", METHODS, vol. 81, 2015, pages 15 - 23
GRATZ ET AL., GENETICS, DOI:10.1534/GENETICS.113.160713, 2014
GUO ET AL., DEVELOPMENT, vol. 141, 2014, pages 707 - 714
GUSEV ET AL., AM. J. PATHOL., vol. 159, no. 1, 2001, pages 63 - 69
HAI ET AL., CELL RES. DOI: 10.1038/CR.2014.11, 2014
HEYDUKHEYDUK, ANALYT. BIOCHEM., vol. 248, 1997, pages 216 - 27
HOHEISEL, NATURE REVIEWS, GENETICS, vol. 7, 2006, pages 200 - 210
HOLZ, O.ZUHLKE, I.JAKSZTAT, E.MULLER, K. C.WELKER, L.NAKASHIMA, M.JORRES, R. A.: "Lung fibroblasts from patients with emphysema show a reduced proliferation rate in culture", EUROPEAN RESPIRATORY JOURNAL, vol. 24, 2004, pages 575 - 579
HWANG ET AL., PLOS ONE, vol. 8, 2013, pages e68708
J. BIOL. CHEM., vol. 274, 1999, pages 3315 - 22
KOJIMAHKUNIMOTO HINOUE TNAKAJIMA K: "The STAT3-IGFBP5 axis is critical for IL-6/gpl30-induced premature senescence in human fibroblasts", CELL CYCLE, vol. 11, no. 4, 2012, pages 730 - 9
KOMAROV PGKOMAROVA EAKONDRATOV RVCHRISTOV-TSELKOV KCOON JSCHERNOV MVGUDKOV AV.: "A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy", SCIENCE, vol. 285, 1999, pages 1733 - 1737, XP000953397, DOI: 10.1126/science.285.5434.1733
LAMBEAU GLAZDUNSKI M: "Receptors for a growing family of secreted phospholipases A2", TRENDS PHARMACOL SCI, vol. 20, 1999, pages 162 - 70, XP004172557, DOI: 10.1016/S0165-6147(99)01300-0
LIEBLER ZIMMERMAN, BIOCHEMISTRY, 2013
LIVAK: "Analysis of relative gene expression data using real-time quantitative PCR and the 2(-AA C(T)) Method", METHODS, vol. 25, no. 4, December 2001 (2001-12-01), pages 402 - 8, XP055567699, DOI: 10.1006/meth.2001.1262
LIZARDI ET AL., NAT. GEN., vol. 19, no. 3, 1998, pages 225 - 232
MA ET AL., CELL RES., vol. 24, 2014, pages 122 - 125
MALI ET AL., SCIENCE, vol. 339, 2013, pages 823 - 826
MANNINO, D. M.BUIST, A. S.: "Global burden of COPD: Risk factors, prevalence, and future trends", LANCET, vol. 370, 2007, pages 765 - 773, XP022223437, DOI: 10.1016/S0140-6736(07)61380-4
MASHIKO ET AL., DEV. GROWTH DIFFER., vol. 56, 2014, pages 122 - 129
MENGMENG WANGXIAOLI LIUZHONGLIN LYUHAO GUDAN LIHONG CHEN: "Glycosaminoglycans (GAGs) and GAG mimetics regulate the behavior of stem cell differentiation", COLLOIDS SURF B BIOINTERFACES, vol. 150, 1 February 2017 (2017-02-01), pages 175 - 182, XP029888961, DOI: 10.1016/j.colsurfb.2016.11.022
MURAKAMI MSATO HMIKIL YYAMAMOTO KTAKETOMI K: "A New Era of Secreted Phospholipase A2 (sPLA2", J LIPID RES, vol. 56, no. 7, 2015, pages 1248 - 61
MURAKAMI, M.T. KAMBE ET AL.: "Functional association of type IIA secretory phospholipase A(2) with the glycosylphosphatidylinositol-anchored heparan sulfate proteoglycan in the cyclooxygenase-2-mediated delayed prostanoid-biosynthetic pathway", J BIOL CHEM, vol. 274, no. 42, 1999, pages 29927 - 36, XP002678580, DOI: 10.1074/jbc.274.42.29927
NALLUR ET AL., NUCLEIC ACIDS RES, vol. 29, no. 23, 2001, pages E118
NEUBACHER ET AL., CHEMBIOCHEM, vol. 10, no. 8, 2009, pages 1289 - 91
NIU ET AL., CELL, vol. 156, 2014, pages 836 - 843
NOUREDDINE, H.GARY-BOBO, G.ALIFANO, M.MARCOS, E.SAKER, M.VIENNEY, NADNOT, S.: "Pulmonary artery smooth muscle cell senescence is a pathogenic mechanism for pulmonary hypertension in chronic lung disease", CIRCULATION RESEARCH, vol. 109, 2011, pages 543 - 553
NYUNOYA, T.MONICK, M. M.KLINGELHUTZ, A. L.GLASER, H.CAGLEY, J. R.RUBERLJ IPEREIRA-SMITH O.A: "A biomarker that identifies senescent human cells in culture and in aging skin in vivo", PROC;NATL.ACAD.SCI., vol. 92, 1995, pages 9363 - 67, XP009065201, DOI: 10.1073/pnas.92.20.9363
SAJICLIUAEBERSOLD: "Using data-independent, high-resolution mass spectrometry in protein biomarker research: perspectives and clinical applications", PROTEOMICS CLIN APPL, vol. 9, 2015, pages 307 - 21
SOLASSOLJACOTLHERMITTEBOULLEMAUDELONDEMANGE: "Clinical proteomics and mass spectrometry profiling for cancer detection", JOURNAL: EXPERT REVIEW OF PROTEOMICS, vol. 3, no. 3, 2006, pages 311 - 320
TSUJI, T.AOSHIBA, K.NAGAI, A.: "Alveolar cell senescence exacerbates pulmonary inflammation in patients with chronic obstructive pulmonary disease", RESPIRATION, vol. 80, 2010, pages 59 - 70
UENO A ET AL., JOURNAL OF HEPATOLOGY, vol. 61, 2014, pages 1080 - 1087
URDEA, NATURE BIOTECHNOLOGY, vol. 12, 1994, pages 926 - 928
VINDRIEUX D ET AL.: "PLA2R1 Mediates Tumor Suppression by Activating JAK2", CANCER RES, vol. 73, no. 20, 2013, pages 6334 - 45
YAMASHITA T ET AL., HEPATOLOGY, vol. 60, 2014, pages 1674 - 1685
YANG ET AL., J. MOL. CELL BIOL., vol. 6, 2014, pages 97 - 99
YOSHIDA, T.TUDER, R. M.: "Pathobiology of cigarette smoke-induced chronic obstructive pulmonary disease", PHYSIOLOGICAL REVIEWS, vol. 87, 2007, pages 1047 - 1082
ZELIADT N, THE SCIENTIST, 2014
ZETSCHE ET AL.: "Cpfl is a Single RNA-guided Endonuclease of a Class 2 CRISPR-Cas System", CELL, vol. 163, 2015, pages 1 - 13

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117269287A (zh) * 2023-11-20 2023-12-22 中国计量科学研究院 一种喷墨进样-毛细管电泳-质谱联用装置及工作方法

Similar Documents

Publication Publication Date Title
JP6599334B2 (ja) 血中循環腫瘍細胞に関する方法およびアッセイ
KR101357033B1 (ko) 도세탁셀에 대한 내성 또는 감수성을 측정하는 방법
US10208351B2 (en) RNY-derived small RNAs as biomarkers for atherosclerosis-related disorders
Pan et al. MicroRNA-124 alleviates the lung injury in mice with septic shock through inhibiting the activation of the MAPK signaling pathway by downregulating MAPK14
EP3271459B1 (fr) Matériels et méthodes pour le traitement de maladies vasculaires
Trian et al. Selective dysfunction of p53 for mitochondrial biogenesis induces cellular proliferation in bronchial smooth muscle from asthmatic patients
US20220160751A1 (en) Methods of treatment of diseases and disorders associated with increased tet level, increased h19 level, increased level of tgf signaling, or any combination thereof
Xia et al. Serum exosomal microRNAs as predictive markers for EGFR mutations in non–small‐cell lung cancer
Li et al. Retracted article: METTL3-mediated mature miR-497-5p/195-5p inhibits trophoblast migration and invasion by targeting WWP1 in preeclampsia
WO2021063968A1 (fr) Procédé et composition pour diagnostiquer une maladie pulmonaire chronique obstructive
Shen et al. Robust temporal changes of cellular senescence and proliferation after sciatic nerve injury
Rasool et al. Loss of LCMT1 and biased protein phosphatase 2A heterotrimerization drive prostate cancer progression and therapy resistance
ES2528672B1 (es) Neurofilina-1 (NRP-1) urinaria como marcador pronóstico de nefritis y nefritis lúpica
US20220026444A1 (en) Methods for diagnosing and/or treating acute or chronic liver, kidney or lung disease
ES2965473T3 (es) Biomarcadores de microARN en suero circulante y métodos para el diagnóstico de la enfermedad de Alzheimer
Hazra et al. The DNA glycosylase NEIL2 plays a vital role in combating SARS-CoV-2 infection
US20170342415A1 (en) Methods for the prevention and the treatment of extracapillary glomerulonephritis
JP2017171641A (ja) 前立腺癌治療剤、前立腺癌診断マーカー及びそれを用いた前立腺癌罹患鑑別方法
EP3009147A1 (fr) Procédé de traitement de glioblastome résistant
CN106460049B (zh) 参与诱导宫颈癌的辅肌动蛋白-4的制药用途
US20200081010A1 (en) Methods and compositions for diagnosing renal cell carcinoma
RU2575076C2 (ru) Фосфодиэстераза 4d7 в качестве маркера для агрессивного гормон-чувствительного рака предстательной железы
WO2020165453A1 (fr) Cible thérapeutique et anticorps monoclonaux dirigés contre celle-ci pour le diagnostic et le traitement de la maladie d'alzheimer
Adnot Pulmonary Artery Smooth Muscle Cell Senescence Is a Pathogenic Mechanism for Pulmonary Hypertension in Chronic Lung Disease
Lemmers et al. Partial loss of colonic primary cilia promotes inflammation and carcinogenesis

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20775906

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20775906

Country of ref document: EP

Kind code of ref document: A1